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 ABSTRACT 
HIV-1 is a retrovirus that causes AIDS, a condition that is characterized by progressive failure of the 
immune system and emerging opportunistic infections. Research aiming at understanding mechanisms 
for retroviral spread and pathogenesis has recently started to focus on the innnate immune system and 
factors that have been demonstrated to either enhance or block infection in tissue-culture experiments. 
The work presented in this thesis aimed to characterize the expression and function of three cellular 
proteins; CD317, SAMHD1, and Siglec-1, that function as modulators of retroviral infection.  
In the first project, we investigated the in vivo expression pattern of the intrinsic immunity factor 
CD317 (BST-2, tetherin) in humans. CD317 restricts the release of enveloped viruses including HIV 
from infected cells. An additional proposed function for CD317 is as a selective target for 
immunotherapy of multiple myeloma, due to its apparently highly restricted expression on the surface 
of terminally differentiated B cells. To facilitate further studies of the biological functions, regulation, 
and therapeutic potential of CD317, we performed microarray-based expression profiling in 468 tissue 
samples from 25 healthy organs from more than 210 patients. CD317 protein could be detected in all 
organs investigated and in a number of specialized cell types, several of which are targeted in vivo by 
pathogenic viruses restricted by CD317 in tissue culture. We found limited co-expression of CD317 
with the IFN biomarker MxA in vivo and low or no stimulation in organ explants exposed to 
recombinant IFNα, indicating that interferons may only partially regulate CD317. The study identified 
multiple thus far unknown interaction sites of viruses with CD317 and refutes the concept of its 
limited constitutive expression and strict IFN inducibility. Furthermore, CD317’s widespread 
expression questions its suitability as a target for immunotherapy. 
The second project involved characterizations of the restriction factor SAMHD1 in resting CD4+ T 
cells. SAMHD1 was reported to potently limit productive HIV-1 infection in a myeloid cell-specific 
manner by restricting HIV at the level of reverse transcription, and this block could be overcome by 
the Vpx protein of SIV and HIV-2. Our study demonstrated that SAMHD1 is also expressed 
abundantly in resting CD4+ T cells, where it locates to both the nucleus and cytoplasm. A staining 
protocol for SAMHD1 detection by flow cytometry was established, which enabled kinetic monitoring 
of its expression at a single cell level. Endogenous SAMHD1 levels were depleted in cells which 
either expressed Vpx following plasmid transfection or infection with Vpx-carrying HIV virions. In 
the latter case the restriction was alleviated, suggesting that reverse transcription is actively suppressed 
in resting CD4+ T cells, and that SAMHD1 is at least partly responsible for this restriction.  
The third project focused on the surface receptor Siglec-1 (sialoadhesin, CD169) that mediates trans-
enhancement of HIV-1 infection through recognition of sialic acid moieties in virus membrane 
gangliosides. Our study demonstrated that mouse Siglec-1, expressed on macrophages, captures 
murine leukemia virus (MLV) particles and mediates their transfer to proliferating B- and T-
lymphocytes. To investigate the interaction between Siglec-1 and virus and its importance for 
mediating trans-infection, we analyzed the potential of sialic acid precursor analogs to modulate the 
MLV/Siglec-1 interaction. MLV released from N-substituted D-mannosamine analog-pretreated cells 
displayed strikingly different capacities for Siglec-1-mediated capture and trans-infection. The N-acyl 
side chain of sialic acid was thus revealed as a critical functional determinant for the mouse Siglec-1-
MLV interaction. 
In conclusion, the findings presented in this thesis provide new insights into the physiological 
expression pattern, regulation and function of the innate immunity factors CD317, SAMHD1 and 
Siglec-1. Characterizing the infection-modifying properties of these proteins might lead to a better 
understanding of their impact on retroviral spread and pathogenesis. 
 
 
ZUSAMMENFASSUNG 
HIV-1 ist ein Retrovirus, das AIDS auslöst, eine Krankheit, die durch progredientes Versagen des 
Immunsystems und damit einhergehenden opportunistischen Infektionen gekennzeichnet ist. Seit 
kurzem stehen Proteine der angeborenen Immunität, die einerseits die Infektion mit HIV-1  in 
Zellkulturexperimenten erleichtern oder andererseits hemmen, im Mittelpunkt derjenigen Forschung, 
die das Verständnis für die retrovirale Pathogenese und Ausbreitung im Körper zum Ziel hat. Die 
vorliegende Arbeit widmete sich der Charakteriserung von Expression und Funktion dreier zellulärer 
Proteine: CD317, SAMHD1 und Siglec-1, welche alle drei den Ablauf der retroviralen Infektion 
modulieren.  
Im ersten Projekt wurde das Muster der in-vivo-Expression des intrinsischen Immunitätsfaktors 
CD317 (BST-2, Tetherin) im Menschen untersucht. CD317 hemmt die Freisetzung behüllter Viren 
wie HIV von infizierten Zellen in Kultur. Zusätzlich wurde CD317 aufgrund seiner hochselektiven 
Expression auf terminal differenzierten B-Zellen als spezifischer Angriffspunkt für die Immuntherapie 
des Multiplen Myeloms diskutiert. Wir erstellten mithilfe eines Microarray-Gewebe-Systems ein 
Expressionsprofil in 468 Gewebeproben aus 25 gesunden Organen von mehr als 210 Patienten. Das 
CD317-Protein konnte in allen untersuchten Organen in mehreren spezialisierten Zelltypen detektiert 
werden; einige dieser sind Zielzellen von pathogenen Viren in vivo, welche von CD317 gehemmt 
werden. Wir fanden nur geringe Koexpression von CD317 mit dem Interferon-Biomarker MxA in vivo 
und nur geringe oder gar keine Stimulation in Organexplantaten, die wir mit rekombinantem IFNα 
behandelt hatten. Diese Befunde legen nahe, dass CD317 allenfalls teilweise von Interferonen reguliert 
wird. Die vorliegende Arbeit identifizierte mehrere bisher unbekannte Interaktionsorte von Virus mit 
CD317 und gibt Grund zum Anlass, das Konzept einer sehr limitierten konstitutiven Expression sowie 
der strikten IFN-Abhängigkeit in Zweifel zu ziehen. Darüber hinaus stellt die ubiquitäre Expression in 
Frage, dass CD317 ein geeigneter Angriffspunkt für immuntherapeutische Ansätze sein könnte. 
Das zweite Projekt untersuchte das antivirale Potential des Restriktionsfaktors SAMHD1in ruhenden 
CD4+-T-Zellen mittels Durchflusszytometrie. SAMHD1 wurde beschrieben, die Infektion von HIV-1 
auf der Ebene der reversen Transkription in Zellen myeloischer Herkunft effizient zu begrenzen; 
dieser Block kann durch die Expression des Vpx-Proteins von SIV oder HIV-2 überwunden werden. 
Die vorliegende Arbeit führte aus, dass – konträr zum angenommenen Expressionsmuster – SAMHD1 
ebenfalls in hohem Maße in ruhenden T-Zellen exprimiert wird, in denen es sowohl im Zellkern als 
auch im Zytoplasma vorkommt. Ein Protokoll zur Anfärbung und Detektion von SAMHD1 mithilfe 
von Durchflusszytometrie wurde etabliert. Dieses gestattete die Untersuchung der antiviralen Aktivität 
auf Einzelzellebene. Endogenes SAMHD1 konnte durch Transfektion von Vpx oder Infektion mit 
HIV-1 oder HIV-2, die Vpx inkorporiert hatten, abgebaut werden. Letzteres führte zu einer Reversion 
der Restriktion in ruhenden T-Zellen und zeigte, dass SAMHD1 zumindest teilweise für diese 
Restriktion verantwortlich ist. 
Das dritte Projekt konzentrierte sich auf den Zelloberflächenrezeptor Siglec-1 (Sialoadhesin, 
CD169), welcher die trans-Infektion von HIV-1 durch die Erkennung von Sialinsäurebestandteilen in 
Gangliosiden der viralen Membran vermittelt. Die vorliegende Arbeit konnte zeigen, dass Maus-
Siglec-1, das auf Makrophagen exprimiert wird, Partikel des murinen Leukämievirus (MLV) 
einfangen und die Übertragung auf proliferierende B- und T-Lymphozyten ermöglichen kann. Um die 
Wechselwirkungen zwischen Siglec-1 und Virus sowie deren Bedeutung für die Vermittlung der 
trans-Infektion zu untersuchen, analysierten wir den Effekt hierauf von Analoga der 
Vorläufersubstanzen der Sialinsäure. MLV, das aus Zellen freigesetzt wurde, die mit N-substituierter 
D-Mannosaminanaloga behandelt worden waren, zeigten deutlich veränderte Fähigkeiten für die 
Siglec-1-vermittelte trans-Infektion. Die N-Alkylseitenkette von Sialinsäure wurde als krtische 
funktionelle Determinante für die murine Siglec-1-MLV-Interaktionen identifiziert. 
Zusammenfassend tragen die in dieser Arbeit vorgestellten Erkenntnisse über das physiologische 
Expressionsmuster, die Regulation sowie die Funktion von CD317, SAMHD1 und Siglec-1 zu einem 
breiteren wie tieferen Verständnis bei. Diese Faktoren der angeborenen Immunität sind Modulatoren 
der Infektion. Die Charakterisierung der infektionsmodulierenden Eigenschaften können einen 
wichtigen Beitrag zum Verständnis von Ausbreitung und Pathogenese retroviraler Infektionen leisten. 
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1 INTRODUCTION  
1.1 INTERPLAY BETWEEN INTRINSIC AND INNATE IMMUNITY IN VIRAL DEFENCE  
1.1.1 Intrinsic immunity and interferon-induced antiviral restriction  
In response to viral infections, host cells have evolved a set of genes that restrict viral replication. 
These genes that encode proteins with suppressive or preventive effects, form part of the intrinsic 
immune system. Contrary to the conventional innate and adaptive immune responses, intrinsic 
immunity does not necessarily need factors that trigger its action – it is already there and active. 
Intrinsic immune factors can be constitutively expressed and can function signal-independent and 
block viral replication directly, thus providing a “front-line immune defense” against infections (14). 
However, some of these conserved intrinsic immunity proteins can also be further induced by type I 
interferons (IFNs). Similar to the induction of the innate immune response, these intrinsic antiviral 
factors require the host to first shape an antiviral state in order to get upregulated, underlying a 
possible interplay between the two types of immune responses. 
   
1.1.2 Viral activation of the IFN system  
Viruses are intracellular pathogens and contain protein as well as nucleic acid structures that are 
recognised as foreign by intracellular pattern-recognition receptors. Recent interest focused on 
recognition of intracellular pathogen-derived nucleic acids. In general, viral RNA as well as DNA can 
be sensed and induce the activation of proinflammatory pathways through IFN secretion. 
 
1.1.2.1 IFN activation through RNA sensors 
Type I IFN genes encode a family of cytokines that comprise 13 IFN-α subtypes and IFN-β (66). 
These genes can be activated by viral DNA and RNA species through recognition by cytosolic pattern 
recognition receptors (PRRs) or endosomal Toll-like receptors (TLRs) that work as microbial sensors 
in the cell. Double standed RNA (dsRNA), for example – which is the genetic material of many 
viruses – can be detected by receptors both in the cytosol and in endosomes. When the cytoplasmic 
sensors retinoic acid inducible gene (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) 
are activated by dsRNA, this leads to phosphorylation, activation and nuclear translocation of 
Interferon regulatory factor (IRF)3 and Nuclear factor κB (NFκB). These proteins are the main 
interferon regulatory transcription factors, which induce transcription of IFNβ genes (84, 211). When 
TLR3 recognizes dsRNA in endosomes, it signals independently of RIG-I and activates IRF3 via the 
adaptor molecule TIR-domain-containing adapter-inducing IFNβ (TRIF), that signals directly to the 
kinase Tank-binding kinase (TBK)1, which phosphorylates IRF3 for nuclear translocation (84). TLR7, 
which recognizes viral single standed RNA (ssRNA), is also located in endosomes and is 
predominantly expressed by plasmacytoid dendritic cells (pDC) and B cells (9, 91). TLR7 (and TLR9, 
which senses double stranded CpG-rich DNA) signal via Myeloid differentiation primary response 
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gene 88 (MyD88) to activate the transcription factor IRF7 (supposedly by phosphorylation (89)), 
which is constitutively expressed in pDC and regulates IFNα/β transcription. Type I IFNs that are 
secreted then bind to interferon cell surface receptors (IFNARs) and activate expression of IFN 
stimulated genes (ISGs) via the JAK-STAT pathway (Fig. 1.1) (84). 
 
Fig. 1.1 Production of an antiviral state. The IFN response circuit is shown as the classical pathway (left) and within pDC 
or B cells expressing TLR7 and 9 (right). Activation of viral sensing receptors leads to expression of type I IFN genes. Type I 
IFNs are secreted and bind to cell surface IFNARs and induce transcription of ISGs (84).  
 
1.1.2.2 IFN activation through DNA sensors 
Signaling events mediated by the presence of intracellular DNA receptors has recently gained 
increasing interest. Besides sensing DNA viruses, recent studies suggest that DNA receptors can also 
be triggered by reverse transcribed retroviral cDNA (61, 102, 146). Cytosolic IFN-inducing DNA 
receptors typically signal through the Stimulator of IFN genes (STING)- dependent pathway. The 
adaptor protein STING resides in the endoplasmatic reticulum and on mitochondria-associated 
membranes (95, 217) and can, upon activation, recruit TBK1 and IRF3 via its C terminus, wich is 
believed to exend into the cytoplasm (Fig. 1.2). TBK1 can thereby phosphorylate IRF3, leading to 
nuclear translocation and induction of IFNβ genes. 
Upstream of STING, many different receptors have been suggested to induce this signalling pathway. 
DNA-dependent activator of IRFs (DAI), also known as ZBP1, was the first candidate DNA sensor to 
be discovered. DAI was found to bind dsDNA and has been reported to interact with TBK1 and IRF3. 
However, DAI has been shown not to play an essential role for DNA sensing in leukocytes and in 
many human cell types (94, 136, 196). Like the RNA sensors RIG-I and MDA5, the DNA sensor 
DDX41 belongs to the DExD/H-Box helicases (DDX) protein family. While RIG-I and MDA5 have 
defined signaling (CARD)- and nucleic acid binding (DDX)- domains, DDX41 is thought to bind 
DNA using its DEADc domain, and also use the same domain to interact with STING (216). 
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Fig. 1.2 Intracellular DNA receptors involved in the induction of interferon-β. Various DNA sensors have been proposed 
to activate a STING-dependent signalling pathway leading to activation of the transcription factors IRF3 and NFκB, which 
trigger transcription of IFNβ mRNA (195). 
 
Not only pathogen-derived DNA or RNA, but also nucleic acids released from host cells during tissue 
damage, have the potential to activate the immune system, and studies on the link between DNA 
damage and innate immune responses indicated that DNA damage events can trigger type I IFN 
induction (112, 118). Later studies then identified the DNA damage factors Meiotic recombination 11 
(Mre11) and the DNA-dependent protein kinase catalytic subunit (DNAPKcs) as initiators of the 
STING-pathway that trigger off repair pathways for dsDNA breaks (125, 195). When it comes to 
sensing of retroviral DNA intermediates, several receptors leading to STING activation have recently 
been identified. The IFNγ-inducible protein 16 (IFI16) and absent in melanoma 2 (AIM2) are 
members of the pyrin and HIN domain-containing (PYHIN) family of proteins, and are able to bind 
DNA via their HIN domains (106). While AIM2 localizes to the cytoplasm and is essential for 
interleukin-1β (IL-1β) production in response to dsDNA and induces the inflammasome, IFI16 
shuttles between the nucleus and the cytoplasm and induces inflammasome activation, as well as 
STING-dependent IFNβ responses upon dsDNA binding (196). According to this mode of activation, 
a role for IFI16 in the recognition of HIV-1-derived dsDNA has been demonstrated (102, 146). It was 
also recently demonstrated that viral intracellular DNA induces the synthesis of a second messenger 
molecule, cyclic GMP-AMP (cGAMP), which can activate STING, leading to IFN induction (186, 
206). The sensor of retroviral – including HIV-1, murine leukemia virus (MLV) and simian 
immunodeficiency virus (SIV) – DNA intermediates was then identified as  the enzyme that 
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synthesizes cGAMP; cyclic GMP-AMP synthase (cGAS), which hence induces IFNβ in a STING-
dependent manner (61).  
 
1.2 INTRINSIC IMMUNE FACTORS AGAINST HIV-1 
1.2.1  Introduction to HIV-1 
1.2.1.1  Discovery and characterization 
HIV-1 was first isolated from human lymph nodes in 1983 and based on its expression of reverse 
transcriptase, its shape and its size, it was classified as a member of the Retroviridae family (7). With 
further cloning and analysis of the genome, HIV-1 was categorized as a member of the genus 
Lentivirus. Like other lentiviruses, HIV-1 has a long period until disease onset and its primary cell 
targets are lymphocytes and macrophages of hematopoietic origin. When phylogenetic analyses of 
HIV-1 viruses from different parts of the world were performed, it became clear that this was a 
genetically extremely variable virus. Most of the variation can be attributed to the surface envelope 
(Env) glycoprotein (see section 1.2.2.2). HIV-1 isolates are divided into four groups: M (main), O 
(outlier), N (non-M, non-O) and P (pending the identification of further human cases). The largest 
group M is further divided into the following subgroups referred to as clades: A, B, C, D, F, G, H, J 
and K, as well as 15 recombinant forms (CRF). Soon after the isolation of HIV-1, lentiviruses were 
discovered and isolated from cats (feline immunodeficiency virus, FIV) (159) and a variety of 
nonhuman primates (simian immunodeficiency virus, SIV) (42). It is now well established that HIV-1 
and HIV-2, a distinct, less pathogenic type of HIV (72), originate from at least two different strains of 
SIV (62): HIV-1 (M) is derived from SIVcpz (infecting chimpanzees, which are apes) and HIV-2 is 
derived from SIVsmm (infecting sooty mangabeys, which are monkeys). These viruses are thought to 
have been transmitted from primates to humans in the beginning of the 20
th
 century (50, 205). 
 
1.2.1.2 The AIDS/HIV pandemic and treatment 
Today, there are more than 34 million people infected with HIV-1 worldwide and every year an 
estimate of 1.8 million people die from AIDS (UNAIDS). The HIV infection begins with an acute 
phase, characterized by high viral loads produced by activated lymphocytes in lymph nodes, which 
give rise to lymph node swelling, a cytokine storm and flu-like symptoms. The acute phase is followed 
by an asymptomatic phase typically starting 3-4 months after infection and this phase is characterized 
by low rate of viral replication and progressive depletion of CD4+ T cells from peripheral blood and 
lymph nodes. The asymptomatic phase may last for years (typically 8-10 years in HIV-1 infection 
(88)), but once the T cell count drops below 200 cells per mL, the untreated disease course enters its 
end stage. In this symptomatic phase, virus replication increases, something which – along with 
chronic immune stimulation – is associated with destruction of lymphoid cells and of the normal 
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architecture of the lymphoid tissue. The infected individual now develops symptoms of AIDS, 
including dysfunction of the immune system and emergence of opportunistic infections.   
The development of anti-retrovirals for slowing the onset of AIDS progressed during the 1990s, and 
now many HIV-1 infected people can live their whole life without developing AIDS (144). These 
drugs are targeting several different steps of the viral life cycle and can thereby keep the viral 
replication low. However, due to factors including lack of education and medical infrastructure, this 
medical treatment is primarily available to HIV-1-infected individuals in developed countries. To 
reduce the rate of HIV-1 transmission globally, development of a prophylactic vaccine to prevent 
infection is of utmost importance. HIV-1 vaccine research is in part focused on the use of vectors 
and/or DNA plasmids aimed at eliciting an effective T cell response or subunit-based vaccines aimed 
at eliciting protective antibodies, or the combination of both (123). Other potential therapeutic 
strategies currently investigated include the use of broadly neutralizing antibodies (bNAbs) that target 
different vulnerable sites on the Env glycoprotein (203), gene editing of the CCR5 gene (189), the 
search for and application of antimicrobial molecules (149) and development of microbicides that can 
be applied topically (134). 
 
1.2.2 Antiviral factors acting at different steps in the HIV-1 life cycle   
1.2.2.1 Viral genes  
Like other lentiviruses, and compared to simple retroviruses, the genome of the integrated form of 
HIV-1 cDNA (provirus) is relatively large (~9.8 kilobases in length), flanked on both ends by a 
repeated sequence known as the long terminal repeats (LTRs). The HIV-1 genome contains more than 
the genes gag, pol and env coding for structural proteins and common to all retroviruses. In order to 
replicate, HIV also needs additional regulatory genes, tat (transactivator of transcription) and rev 
(regulator of expression of virion proteins). The four remaining genes; vif (viral infectivity factor), vpu 
(viral protein U), vpr (viral protein R) and nef (negative factor), encode accessory proteins that are not 
essential for replication in tissue culture, but seem to have a larger impact on virus production and 
pathogenesis in vivo. Many SIVs and HIV-2 encode one additional accessory gene, vpx (viral protein 
X), which is related to Vpr and thought to have arisen as a result of non-homologous recombination 
between different SIVs (180). 
  
1.2.2.2 The viral particle and its life cycle 
Each HIV-1 particle contains a set of structural as well as non-structural proteins, and the HIV-1 viral 
assembly and replication cycle requires the collaborate effort of its genes that encode both structural 
and non-structural proteins (55). The gag gene encodes Gag (p55), a polyprotein precursor that is 
cleaved by the viral protease (PR) into the mature Gag proteins matrix (MA/p17), capsid (CA/p24), 
nucleocapsid (NC/p7), p6, spacer peptide p1 and p2. Gag (p55) proteins assemble together with Gag-
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Pol polyprotein precursor Gag-Pol (p160) which is the result of a rare frame shift during Gag (p55) 
translation. Gag-Pol contains the viral enzymes; protease (PR), integrase (IN) and reverse transcriptase 
(RT), which are cleaved during maturation. The envelope (Env) glycoproteins are also synthesized 
from the Env precursor (gp160) that is processed by a cellular protease resulting in the generation of 
the surface (SU) Env glycoprotein gp120 and the transmembrane (TM) glycoprotein gp41. The 
structural proteins; MA, CA, NC and p6 (Gag) assemble together with the viral enzymes; PR, IN and 
RT (GagPol); and the envelope glycoproteins are incorporated into budding viral particles at the 
plasma membrane. In addition to these structural and enzymatic proteins, also the accessory protein 
Vpr is incorporated into new virions through interaction with p6 in Gag and in the case of HIV-2, also 
Vpx is incorporated.  
The HIV particle is covered by a lipid bilayer, derived from the host cell membrane during the 
budding process. When HIV-1 enters the cell, the Env subunit gp120 interacts with CD4 on the cell 
surface, resulting in a conformational change that allows binding of the chemokine receptors CCR5 or 
CXCR4. Following this interaction, either the virus membrane fuses with the cellular membrane so 
that its core can be released into the cytoplasm, or the clathrin-mediated endocytosis process is 
triggered. When the HIV-1 core is uncoated (a process which is still poorly understood (13, 208)), this 
leads to formation of the reverse transcription complex (RTC), containing the viral RNA and the 
proteins needed for reverse transcription (20, 51). The viral RNA is then converted into (linear) 
double-stranded DNA, and the pre-integration complex (PIC) travels through the nuclear pore 
complex into the nucleoplasm, where the viral genome integrates into the host genome by the 
enzymatic activity of IN. Once the transcription of the proviral DNA template is initiated in the HIV 
long terminal repeat (LTR), the binding of the cellular RNA polymerase II in presence of the 
regulatory protein Tat leads to efficient transcriptional activity. The viral RNAs that are generated 
during transcription resemble cellular mRNAs but can be fully spliced, unspliced or partially spliced. 
The process in which partially spliced or unspliced mRNAs are transported from the nucleus into the 
cytoplasm requires the presence of the viral regulatory protein Rev (164) and the cellular factor CRM1 
(56). Rev binds to the Rev-response element, leading to unrecognized export of partially spliced 
mRNAs which would otherwise be recognized by host cell mechanisms including e.g. nonsense-
mediated decay. After viral protein synthesis at the ribosomes, the proteins are transported to the cell 
membrane where the virus assembles. The Gag protein binds tRNA to its MA domain – this prevents 
that Gag binds to intracellular membranes, thereby facilitating recruitment to the plasma membrane – 
and it also recruits both cellular and viral transcripts to the plasma membrane via its NC domain. At 
the plasma membrane the viral genomic RNAs are selectively incorporated into virions due to specific 
A-rich nucleotide sequences (129). When all viral components have assembled, a budding process is 
initiated by interaction of Gag polyprotein parts with the cellular ESCRT machinery and the viral 
particles pinch off from the cell membrane, resulting in the onset of the final steps necessary to 
generate infectious particles. The Gag polyprotein is then processed into its subunits MA, CA, NC and 
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p6. In this process, called maturation, structural changes occur that allow the virion to enter, uncoat 
and replicate in the next host cell: the RNA genome is condensed and stabilized and the conical capsid 
assembles around the RNA-NC-complex (187). During this life cycle, host cell restriction factors can 
act at virtually all steps. However, many restriction factors inhibit incoming viral capsids or reverse 
transcription complexes, suggesting that the very early steps are vulnerable targets for intrinsic 
immune factors. 
         
1.2.2.3 HIV-1 restriction factors  
Common traits shared by HIV-1 restriction factors are that they typically act in a species specific way, 
are under positive selection, and often IFN-inducible (140). One antiretroviral restriction factor whose 
expression is increased as a consequence of IFN treatment is the ubiquitin ligase Trim5α, which 
belongs to the Trim (tripartite interaction motif) family of proteins. Trim5α blocks HIV-1 replication 
in rhesus macaques, likely by targeting its capsid protein for degradation by the proteasome (191). 
Since some lentiviral capsids bind to the host cell protein cyclophilin A (CypA), the sensitivity of 
TRIM5α towards HIV-1 is compromised.  Additionally, while human Trim5α largely lacks the ability 
to bind HIV-1 capsid, productive infection of nonhuman primate cells with HIV-1 is efficiently 
restricted (46). In general, TRIM5α proteins are poor inhibitors of retroviruses that are found naturally 
in the same host species, but are often active against retroviruses that are found in other species, a 
common feature of species-specificity of restriction factors.  
Different restriction factors target different steps of viral replication. For instance, several members of 
the APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic polypeptide 3) family of genes are 
also interferon-inducible and impose their restriction by targeting retroviral replication at the level of 
reverse transcription. When viral RNA is copied into cDNA, APOBEC3G/F deaminate the single 
stranded DNA, converting cytosine to uracil (U) resulting in the pairing of U’s with A’s. Since uracil-
containing DNA is less stable, it usually gets degraded. However, if it stays intact and the provirus 
gets integrated into the host genome, the mutations will in many circumstances prevent it from 
producing viable progeny. Furthermore APOBEC3G has a preference for GG dinucleotides (141) and 
that means TGG (tryptophan) codons can be converted into stop-codons (TAA). In addition to the 
deaminating activity, A3G also has a deamination-independent antiviral activity by blocking reverse 
transcription, likely through interacting and physically preventing elongation of RT (15). In order to 
replicate successfully, viruses have evolved strategies to overcome these cellular barriers of the host. 
For example, the HIV-1 accessory protein Vif accomplishes this by binding both APOBEC3G and 
proteins cullin 5 and elongins B and C, belonging to an E3 ubiquitin ligase complex, thus resulting in 
the polyubiquitination of APOBEC3G and proteasomal degradation (213).  
Another factor recently found to have anti-HIV-1 activity is the type I interferon-inducible human 
protein MX2 (74, 111, 137). MX2 seems to act at the level of nuclear import and/or at the level of 
integration (49, 74), because in MX2-expressing cells the cDNA synthesis occurs normally, while 
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integration of HIV-1 provirus is impaired. Similar to TRIM5α, MX2’s anti-HIV activity seems to be 
sensitive to capsid-CypA binding. However, since the viral inhibition is manifested as the failure to 
accumulate viral cDNA in the nucleus, the anti-viral action of MX2 is distinct from TRIM5α- or 
APOBEC3G-mediated inhibition of early reverse transcription or SAMHD1-mediated restriction (see 
next section) (74).  
 
1.2.2.4 SAMHD1 
The sterile alpha motif (SAM) domain and HD domain-containing protein 1 (SAMHD1) has been 
reported to potently restrict productive HIV-1 infection at an early stage of the viral replication cycle 
in non-dividing cells of myeloid origin, like monocytes, macrophages and DC (92, 131) and this block 
is overcome by the Vpx protein of SIV and HIV-2 through a proteasome-dependent mechanism 
involving DCAF1 and DDB1 (1, 92, 184). Vpx has also been described to promote the nuclear entry 
of the PIC and the accumulation of full-length viral DNA (54, 58). The HIV-1 replication block in 
myeloid cells and the delivery of the Vpx protein to overcome this restriction, has been known for 
some time (73, 75, 179). The interaction of Vpx with DCAF1, a component of the 
CRL4A/DDB1/DCAF1 ubiquitin ligase complex, and the involvement of the proteasome system are 
required for the Vpx-dependent enhancement of infection (75, 179, 184). Vpx is believed to primarily 
counteract SAMHD1 by CRL4A/DDB1/DCAF1 ubiquitin ligase-dependent degradation of the 
restriction factor, rendering non-cycling myeloid cells permissive for infection (11, 184). 
The block imposed by SAMHD1 is at the  level of reverse transcription, during which the HIV-1 RNA 
is copied into cDNA. The HD-domain of SAMHD1 has nucleotide-phosphohydrolase activity (3), and 
SAMHD1 is a dGTP-stimulated triphosphohydrolase that can dehydrolyze deoxynucleoside 
triphosphates (dNTPs) into deoxynucleoside and triphosphate thus postulated to lower the dNTP pool 
levels enough to sufficiently reduce viral DNA synthesis in non-cycling cells (166). The HD-domain 
alone has also been shown to be sufficient to restrict infection of different viruses (204). Thus the 
findings on SAMHD1 restriction activities suggested that the overall decrease in the level of dNTPs 
may be primarily responsible for the block imposed on lentiviral reverse transcription. A second 
enzymatic activity was recently described for the HD-domain of SAMHD1; it also posesses nuclease 
activity by which it can target single-stranded DNA and RNA (10), and an even more recent study 
suggests that SAMHD1 inhibits HIV-infection through degradation of viral RNA rather than through 
its dNTPase activity (175). Furthermore, the SAMHD1 restriction activity has been demonstrated to be 
determined by its phosphorylation status, which correlates with whether the cells are cycling 
(phosphorylated SAMHD1) or non-cycling (dephosphorylated SAMHD1) (34). The phosphorylation 
site on SAMHD1 has been mapped to residue T592 and phosphorylation at this site renders SAMHD1 
incapable of blocking retroviral infection (34). However, the modification of this phosphorylation site 
does not affect the ability of SAMHD1 to decrease cellular dNTP levels (204). The ribonuclease 
activity, on the other hand, was described to be negatively regulated by phosphorylation at residue 
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T592 (175). Hence the mechanistic details on antiviral restriction imposed by SAMHD1 are still not 
fully elucidated and remain an active field of research.   
 
1.2.2.5 Tetherin/CD317  
Though originally discovered as a plasma cell antigen highly expressed by multiple myeloma cells 
(71), and later suggested as a target for cellular immunotherapy (103), CD317 (also known as BST-2, 
Tetherin or HM1.24) was not identified as an antiviral restriction factor until 2008. Tetherin inhibits 
the release of retroviruses and its action is antagonized by the HIV-1 accessory protein Vpu (153, 
198). When infected with HIV-1, some cell lines, e.g. HeLa cells, require Vpu for efficient viral 
particle release, while others do not require the action of this viral accessory protein for final release 
from the cell surface. Vpu has mainly two functions; 1) it interacts with newly synthesized CD4 (the 
primary receptor for all primate lentiviruses) at the endoplasmatic reticulum (ER) and  targets the 
receptor for proteasomal degradation, 2) Vpu  enhances the release of viral particles by counteracting 
CD317. The latter is mechanistically not fully understood but may involve targeting CD317 for 
proteasomal and/or lysosomal degradation or the sequestration of CD317 resulting in reduction of its 
cell surface exposure (67). CD317 is a glycosylated type II transmembrane protein of 30-36 kDa. It 
has an unusual topology, shared only by a minor isoform of the prion protein (147). CD317 has a short 
N-terminal domain that is cytoplasmic, a transmembrane region that anchors the protein in the 
membrane and a coiled-coil extracellular domain prior to the C-terminus of the protein. The C-
terminus has a glycosylphosphatidylinositol (GPI) anchor that enables the protein to localize to lipid 
rafts at the plasma membrane, a site where HIV budding preferentially occurs (128). CD317 localizes 
not only to the plasma membrane, but also to membranes on intracellular organelles, including 
endosomes and the trans-Golgi network (83). Mechanistically, the tethering action of the CD317 
protein is thought to involve one or both of its anchors to become incorporated into the viral particle 
while the extracellular coiled-coil domain typically forms homodimers. Thereby can CD317 
efficiently tether enveloped viral particles to the cell surface (160). In addition to the tethering action, 
reports have also demonstrated a role for CD317 in signal transduction (59, 190). These studies show 
that CD317-mediated restriction of the release of enveloped viruses triggers proinflammatory gene 
expression through induction of NfκB activation. Both the extracellular domain that is essential for 
virus restriction, and amino acids in the N-terminal cytoplasmic tail, were required for NFκB-mediated 
transcription of proinflammatory genes (59).       
In addition to HIV-1, several other enveloped viruses are also restricted by CD317 and have evolved 
counteracting factors to overcome the impaired release of budding virions from the cell surface. In 
contrast to HIV-1, most other primate lentiviruses do not contain a vpu gene, neither HIV-2 nor SIV 
encode a Vpu protein, instead they use Env (HIV-2, SIV) and Nef (SIV) to antagonize CD317 (133, 
153, 215). Ebola virus uses its glycoprotein (109) and Kaposi’s sarcoma herpesvirus (KSHV) has been 
suggested to use its protein processing K5 ubiquitin ligase activity (142) to circumvent the block that 
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CD317 constitutes. Since most other primate lentiviruses do not contain a vpu gene while HIV-1 does, 
this may have important implications for the role of Vpu in the  pathogenesis of AIDS (121, 128). 
Recent studies describe how Nef proteins of HIV-1 group O – which is believed to be derived from a 
different ancestor than group M and has not evolved a Vpu-based tetherin antagonism (176) – can 
antagonize human CD317, and this is something that might explain the epidemic spread of HIV-1 
group O (124).  
 
1.3 CARBOHYDRATE RECEPTORS AND RETROVIRAL TRANS-INFECTION 
1.3.1 DC-SIGN and the concept of trans-infection 
The important role of dendritic cells (DC) in HIV infection came from the discovery that these cells 
facilitate HIV infection when cocultured with T cells  (23, 165). This process, whereby uninfected 
immature DC (23, 76) capture virus and mediate viral transfer to neighboring cells without becoming 
infected themselves is termed trans-infection. The HIV glycoprotein gp120 binds to dendritic cell–
specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) (41, 64), a cell surface C-
type lectin expressed on immature dendritic cells, mostly present in skin and mucosa. Isolated primary 
DC-SIGN+ cells from rectal mucosa were shown to mediate transmission of HIV-1 to T cells through 
DC-SIGN (82), this confirming a role of the receptor as a mediator of transmission of HIV in 
physiologically relevant cells. DC-SIGN is expressed as a tetramer and recognizes mannose, fucose, 
N-Acetylglucosamine (GlcNAc) and mannan, through a Ca2+-dependent mechanism (52). In contrast 
to CD4 and chemokine receptors, DC-SIGN does not mediate entry of HIV bound to it (64, 130). 
However, at low viral multiplicty of infection (MOI), DC-SIGN-expressing cells pulsed with HIV 
transmit virus to appropriate target cells and retain infectious particles for several days in culture. 
After binding, the DC-SIGN cytoplasmic tail mediates internalization of HIV, keeping it intact for 
efficient infection in trans in a low pH nonlysosomal compartment (130). Later studies on DC transfer, 
however, demonstrate that the long-term transfer of HIV require infection of the DC and show that de 
novo synthesized viral particles are primarily transferred to T cells at the later time points (21, 26). 
These more recent studies distinguish between a first-phase transmission, which occurs early and 
peaks within the first couple of hours after virus exposure, and a second phase, in which virus can be 
transmitted up to 5 days after exposure (26, 194). The latter one is supposed to involve the de novo 
pathway of viral transmission, while the early phase trans-infection is characterized by transfer of 
primarily surface-bound HIV particles to CD4+ T cells (21, 26).  
Since DC-SIGN is expressed at high levels on immature dendritic cells, it is suggested to be important 
for DC-mediated transport of virus from mucosal sites to secondary lymphoid tissues where it could 
efficiently transfer virus to T cells (64). DC-SIGN is able to capture and enhance transmission of a 
variety of HIV and SIV strains, but cannot bind to HIV particles pseudotyped with the retroviral 
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ecotropic Moloney murine leukemia virus (MLV) envelope glycoprotein (130), this suggesting some 
species specificity. Although the function of DC-SIGN to capture and transfer HIV-1 particles to 
CD4+ T cells is well established (4, 64, 82, 130), some studies question the actual contribution of DC-
SIGN in HIV trans-infection, since virus transfer can occur through DC-SIGN-independent 
mechanisms as well (6, 80, 207). These studies used monocyte-derived DC, suggesting that other 
receptors expressed on this in vitro-differentiated cell type are contributing to the trans-infection of 
HIV-1. Indeed, studies suggested several other receptors (e.g galactosyl ceramide, the mannose 
receptor, the HIV-1 receptor CD4 and Syndecan-3) to be involved (43, 139, 154, 193). Recent studies 
have also demonstrated an important role for the sialic acid-binding immunoglobulin-like lectin 1 
(Siglec-1) in HIV-1 trans-infection mediated by monocyte-derived DC (see section 1.3.3). In order to 
define the role of different receptors in HIV trans-infection and their potential effect on HIV 
transmission in vivo, isolation of primary DC subsets from tissues relevant for HIV-transmission (e.g. 
subepithelium of the genital and rectal mucosa) would be required, the difficulty of which makes such 
studies demanding to conduct. 
    
1.3.2 Siglec-1/Sialoadhesin/CD169 
1.3.2.1 Discovery and characterisation 
The adhesion molecule and carbohydrate recognition receptor Siglec-1, also termed Sialoadhesin or 
CD169, was first described in 1985 as a non-phagocytic sheep erythrocyte receptor, expressed on 
resident bone marrow macrophages that cluster with developing haematopoietic cells (36). Therefore, 
Siglec-1 was suggested to directly regulate haematopoiesis (40), and later studies by Chow et al. 
showed Siglec-1+ bone marrow macrophages to be important for erythroblast development (29, 30). 
However, Siglec-1 -/- mice are viable and show no developmental abnormalities. They have a small 
increase in CD8+ T cells and a small decrease in B220+ B cells in spleens and lymph nodes with 
slightly less follicular B cells and an increase in numbers of marginal zone B cells in spleen, a 
phenomenon indicative of reduced immunoglobulin M (IgM) levels (155).  
There are 14 Siglecs in humans and they all recognize sialic acids. Being the largest member of the 
immunoglobulin (Ig) superfamily, Siglec-1 is a type I transmembrane glycoprotein and has 17 Ig-like 
domains, with 16 extracellular C2-like domains extending from the cell surface and one extracellular 
N-terminal V-set domain at the top. The V-set domain was shown to be necessary and sufficient for 
sialic acid binding (152). Unlike most other Siglecs, Siglec-1 has a short, poorly conserved 
cytoplasmic tail that lacks tyrosine-based signalling motifs, suggesting a primary role as binding 
partner in cell-cell interactions rather than cell signaling (38). 
Sialic acids are typically located at the exposed ends of oligosaccharide chains, and Siglec-1 binding is 
influenced by the type of sialic acid and its linkage to the subterminal sugar. In glycoproteins and 
glycolipids, sialylated oligosaccharide ligands are attached to protein and lipid carriers. These 
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glycoconjugates have the potential to function as ‘counter-receptors’ for Siglecs and other glycan-
binding proteins (35, 38). Siglec-1 preferentially recognizes sialic acids that are α2 → 3 linked, which 
means that the gangliosides GD1a and GM3 which express terminal α2 → 3 linked sialic acid are 
recognized by Siglec-1, whereas GM1 and GM2 which express a less exposed sialic acid residue, and 
GD3 and GQ1b which contain terminal α2 → 8 linked sialic acid, do not bind at all or only weakly 
(37). Studies that investigated the interaction between Siglec-1 and one of the most common sialic 
acids in mammals, N-acetylneuraminic acid (Neu5Ac), demonstrated by site-directed mutagenesis 
(200), X-ray crystallography (143), and NMR (39) that the arginine-97 residue (which is conserved in 
Siglec-1 in all species) forms a key salt bridge with the carboxylate group of Neu5Ac and two 
conserved tryptophans at positions 2 and 106 to make hydrophobic interactions with the N-acetyl 
group and the C-9 glycerol group respectively (Fig. 1.3).   
  
 
Fig. 1.3 The features of N-acetylneuraminic acid important for interaction with Siglec-1. Indicated are the functional 
groups that form contacts with the binding site of Siglec-1. The Siglec-1 residues indicated are conserved in all Siglec-1 
orthologs (122).  
The functional groups of sialic acids involved in binding to Siglec-1 were investigated using synthetic 
N-acetylneuraminic acid analogues either on resialylated human erythrocytes or as free α-glycosides in 
hapten inhibition studies (115, 116). These studies confirmed that Siglec-1 specifically binds Neu5Ac, 
but does not recognize two other important sialic acids; Neu5Gc or Neu5Ac9Ac. In contrast to mice, 
humans lack Neu5Gc due to a mutation in the CMAH (cytidine monophosphate-N-acetylneuraminic 
acid hydroxylase) gene, which encodes the enzyme required for the conversion of Neu5Ac to Neu5Gc 
(183).  
 
1.3.2.2 Expression profile and IFN induction 
In humans, Siglec-1 is expressed on tissue macrophages in the spleen, lymph nodes, bone marrow, 
liver, colon and lungs (86). In rodents, Siglec-1 is abundantly expressed on macrophages in the 
subcapsular sinus (SCS) and medullary cords of the lymph node (Fig. 1.4), as well as on marginal 
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zone metallophilic macrophages in the spleen. Their strategic localization along lymphatic vessels and 
at portals of entry for blood, suggests a function for these cells in regulating the immune response to 
pathogens that they encounter in the lymph and in blood.   
 
 
Fig. 1.4 Lymph node macrophages localize to strategic positions. Diagram showing anatomical distribution of lymph node 
sinus-resident macrophages along with the surface markers they express (127). 
 
IFN alpha has been shown to upregulate Siglec-1 expression on macrophages in all species examined. 
In addition, molecules that trigger type I IFN responses like LPS and poly I:C stimulation of TLR4 
and 3, respectively, have this effect by activating the TRIF-dependent pathway of type I IFN induction 
(212). Although there is no in vivo evidence for DC expression of Siglec-1, it can be induced on 
monocyte-derived DC in vitro after treatment with inactivated human rhinovirus (119) or after LPS or 
type I IFN stimulation (100, 168). Siglec-1 has also been reported to be expressed on monocytes in 
patients suffering from viral infections or autoimmune diseases with upregulated type I IFN levels as a 
marker, like HIV-1 infection (167, 199), systemic lupus erythematosus and systemic sclerosis (212).     
 
1.3.3 The role of Siglec-1 in viral infection 
Siglec-1 is a surface receptor involved in trans-enhancement of HIV-1 infection and its expression on 
monocytes directly correlates with plasma viral load in HIV-1 patients (170). Siglec-1 was shown to 
bind the virus through recognizing the sialic acid residues on the viral envelope glycoprotein gp120. 
The Siglec-1+ monocytes enhanced HIV-1 infectivity by absorbing the cell-free virus from the culture 
and trans-infecting permissive reporter cells. In another study, the sialic acid on gp120 binding to 
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Siglec-1 was shown to have a crucial role in infection of macrophages (218). However, it was recently 
demonstrated that Siglec-1 expressed on in vitro differentiated DC can recognize sialic acid-containing 
gangliosides in the HIV-1 particles, independent of gp120 leading to capture, internalization and 
subsequent transfer to target cells (98, 100, 168, 169). The ganglioside recognized by Siglec-1 in these 
studies was GM3, a glycolipid that had previously been observed in the membranes of HIV-1 and 
several other viruses including Semliki forest virus (SFV), vesicular stomatitis virus (VSV) and MLV 
(27, 98, 110). Mouse studies show that within minutes upon peripheral inoculation, viral particles are 
captured by lymph node resident (CD169++) sinus macrophages, preventing their systemic 
dissemination (93, 108). While (CD169+) medullary macrophages are poorly selective in their 
filtering ability and can bind bacteria, nanoparticles and apoptotic cells, the subcapsular sinus 
macrophages seem to be specialized in binding viruses and immune complexes (77). As compared to 
medullary macrophages, the subcapsular sinus macrophages are less endocytic and able to retain viral 
particles on their surface for at least several hours after capture (108, 161, 171, 192), through a yet not 
understood mechanism. Most of the in vivo studies on viral capture in mice have been perfomed using 
VSV, a rhabdovirus causing fatal paralytic disease in mammals. When VSV is captured by 
subcapsular sinus macrophages, the virus can readily replicate in these cells, something that was 
shown to be critical for host survival: the enforced viral replication at this site results in that the 
macrophages – before being killed by the cytopathic VSV – secrete large amounts of IFNα/β that 
establishes a local antiviral state, this preventing further viral replication, thereby protecting the host 
from central ascending nervous system paralysis and death (93, 148). There are also mechanisms 
attributed to subcapsular sinus macrophages that are not dependent on virus replication in these cells, 
that might affect viral pathogenesis. For instance the local accumulation of virus and increased antigen 
availability may promote adaptive immunity (87, 90) and it has also been described in a study that 
subcapsular sinus macrophages can translocate surface-bound viral particles across the subcapsular 
sinus floor (which is normally impermeable to particles larger than 4 nm, such as viruses (57)) and 
present them to migrating B cells in underlying follicles (108). In this study, it was demonstrated that 
after infection, virions were detectable at B cell-macrophage interfaces for at least 4 hours, and the 
authors suggest that particles probably reached the lymph node parenchyma by moving along the 
macrophage surface. Interestingly, while the above mentioned studies investigated the function of the 
Siglec-1+ subcapsular sinus macrophages to capture and retain virus particles, none of the studies 
attributed this function to the Siglec-1 receptor itself.    
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2 OBJECTIVES  
2.1 OVERALL AIM OF THIS THESIS 
The work presented in this thesis aimed to characterize the expression and function of cellular proteins 
working as modulators of retroviral infection. Investigating these cellular factors using primary cells 
and ex vivo tissue models could lead to a better understanding of the in vivo determinants of retrovirus 
transmission and viral spread. 
   
2.2 PROJECT-SPECIFIC AIMS 
2.2.1 In vivo expression profiling of CD317 
CD317 was originally referred to as bone marrow stromal antigen 2 (BST-2) because it was found to 
be expressed by bone marrow stromal cell lines (96). Moreover, the protein has previously been 
described to be constitutively expressed by some human cancer cells, e.g. from breast cancers (22) and 
multiple myelomas, as well as by terminally differentiated B-cells (71). In mice, CD317 is a marker 
for pDC (16), but the protein has also been shown to be expressed by mouse plasma cells (188). 
However, most expression studies of the restriction factor have focused on IFN induction in cell lines 
or isolated primary T cells normally expressing no or low levels of CD317, trying to assess whether 
viral target cells have the ability to upregulate the protein after IFN treatment. Focusing on the 
antiviral activities of CD317, it is important to investigate expression of the restriction factor in vivo, 
since a broader knowledge about which cell types express the protein either constitutively or after 
induction would help to understand more about its antiviral potential under physiological conditions. 
Furthermore, considering that CD317 is suggested as a specific target for immunotherapy in B-cell 
malignancies (103), detailed knowledge of its full expression pattern is essential in order to avoid 
potential side effects. This project aims to address questions regarding in vivo-expression levels and 
tissue distribution of CD317 under physiological conditions. 
  
2.2.2 Investigating the antiviral activity of SAMHD1 in resting T cells by flow cytometry 
SAMHD1 was recently reported as a potent restriction factor that limits productive HIV-1 infection in 
monocytes and dendritic cells. Interestingly, CD4+ T cells in a resting state are largely refractory to 
HIV-1 infection and only become permissive upon activation (185, 214). The first aim therefore of my 
studies on SAMHD1 was to determine whether, in contrast to its proposed cell type-specific 
expression pattern, SAMHD1 is also expressed in resting CD4+ T cells. Furthermore, the focus was on 
deciphering the antiviral role of SAMHD1 in the T cell lineage using different experimental strategies 
including monitoring SAMHD1 levels during the course of an infection, and establishing a flow 
cytometry compatible protocol to investigate SAMHD1 in vivo-expression levels in specific cell types. 
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2.2.3 The role of murine Siglec-1+ macrophages in retroviral trans-infection   
To investigate whether the ability of Siglec-1 to transfer virus to lymphocytes that get productively 
infected is common for retroviruses other than HIV-1, the aim of the third project was to explore the 
potential role of mouse Siglec-1 in modulating the infection of murine leukemia virus (MLV). An ex 
vivo co-culture system was established where wild-type or Siglec-1-/- bone marrow-derived 
macrophages (BMDM) are pulsed with virus and co-cultivated with mouse lymphocytes. In order to 
investigate which binding properties are necessary for viral transfer, dependency of the sialic acid N-
acyl chain was tested by pretreatment of cells with sialic acid precursor analogs to biosythetically 
incorporate N-acyl-modified sialic acids in the virus producer cells, and consequently in the MLV 
membrane. This project aimed to contribute to a deeper understanding of the role of Siglec-1 in 
retroviral trans-infection and the determinants of virus-cell interaction, something that could be 
important for viral spread and pathogenesis in vivo.      
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3 MATERIAL AND METHODS 
3.1 MATERIAL 
3.1.1 Antibodies 
Table 1. Primary antibodies used in this work. 
Unconjugated Antibodies 
Antibody Species Clone Dilution (application) Source 
mAbα-CD3 rabbit IgG SP7 1:200 (IF) Neo Markers 
mAbα-CD3 mouse IgG2a PS1 1:500 (IF) BioGenex 
mAbα-CD4 mouse IgG1 IF6 1:25 (IF) Invitrogen (Zymed) 
mAbα-CD14 mouse IgG1 2Q1233 1:25 (Flow) Abcam 
mAb α-CD19 mouse IgG1 LE-CD19 1:100 (IF) Acris 
mAb α-CD21 mouse IgG1 1F8 1:50 (IF) Dako 
mAb α-CD23 mouse IgG1 1B12 1:10 (IF) Neo Markers 
mAb α-CD31 mouse IgG1 JC70A 1:25 (IF) Dako 
mAb α-CD66b mouse IgG1 80H3 1:100 (IF) Dianova 
mAb α-CD68 mouse IgG3 PG-M1 1:100 (IF) Dako 
mAb α-CD138 mouse IgG1 MI15 1:25 (IF) Dako 
mAb α-DC-SIGN mouse IgG1 AZN-D1 1:100 (IF) Teunis Geijtenbeek 
mAbα-CD303/BDCA2 mouse IgG1 124B3.13 1:50 (IF) Dendritics 
mAbα-D2-40 mouse IgG1 D2-40 1:50 (IF) Dako 
mAbα-CD106 mouse IgG1 51-10C9 1:50 (Flow) BD Pharmingen 
pAbα-sIgD rabbit IgG  1:1500 (IF) Dako 
mAbα-HM1.24/CD317 mouse IgG2a HM1.24 1:200 (IHC, IF); 1:400 (Flow) Chugai Pharmaceuticals 
mAbα-CD317/BST2 mouse IgG1 26F8 1:50 (IHC) eBioscience 
pAb α-BST-2/CD317 rabbit IgG  1:5000 (WB) Klaus Strebel 
pAb α-SAMHD1 rabbit IgG  1:100 (IHC, FACS) Proteintech Europe 
pAbα-TRIM5α rabbit IgG  1:400 (IHC) LifeSpan Biosciences 
pAbα-TRIM5γ rabbit IgG  1:400 (IHC) LifeSpan Biosciences 
pAbα-MXA rabbit IgG #166 1:500 (IHC, WB) Otto Haller, Georg Kochs 
mAbα-MXA mouse IgG2a M143 1:1000 (WB) Otto Haller, Georg Kochs 
pAbα-MLV p30 rat IgG R187 1:50 (Flow) Sarah S, AG Keppler 
(Hybridoma from  Carol 
Stocking, via Jens 
Bohne) 
pAbα-ERK 2 rabbit IgG  1:1000 (WB) Santa Cruz 
Biotechnology 
mAbα-mSiglec1 rat IgG2a  1:100 (blocking, IF) Aviva Systems Biology 
     
Conjugated Antibodies 
Antibody Species Conjugate Dilution Source 
α-CD3 Mouse PE 1:20 (IF, Flow) BD Biosciences 
α-CD4 Mouse PE 1:20 (Flow) BD Biosciences 
α-CD14 Mouse PE 1:20 (IF, Flow) BD Biosciences 
α-CD19 Mouse PE 1:20 (IF, Flow) BD Biosciences 
α-CD138 Mouse PE 1:20 (Flow) Miltenyi Biotech 
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α-BDCA2 Mouse FITC 1:50 (Flow) Miltenyi Biotech 
α-mCD3 rat APC 1:20 (Flow) BD Biosciences 
α-mCD19 rat PE 1:20 (Flow) BD Biosciences 
α-mCD169 rat PE 1:40 (Flow) eBiosciences 
α-mCD169 rat Alexa 647 1:100 (IF) Aviva Systems Biology, 
Invitrogen 
 
Table 2. Secondary antibodies and detection conjugates used in this work. 
Antibody/Reagent Species Conjugate Dilution Source 
α-mouse IgG donkey Biotin 1:100 (IHC, IF) Amersham 
α-mouse IgG sheep Biotin 1:100 (IHC, IF) Amersham 
α-mouse IgG1 donkey Cy2 1:50 (IF) Jackson ImmunoResearch 
α-rabbit IgG donkey Biotin 1:200 (IHC, IF) Jackson ImmunoResearch 
α-rabbit IgG donkey  1:200 (IHC, IF) Jackson ImmunoResearch 
α-rabbit goat Alexa 660 1:200 (Flow, IF) Invitrogen 
α-rabbit goat Alexa 488 1:500 (IF) Invitrogen 
α-goat donkey Alexa 488 1:500 (IF) Invitrogen 
α-mouse goat Alexa 488 1:500 (IF) Invitrogen 
α-rat donkey Alexa 488 1:200 (Flow) Invitrogen 
Streptavidin  Cy3 1:1000 (IF) Jackson ImmunoResearch 
Streptavidin  Cy2 1:50 (IF) Jackson ImmunoResearch 
α-mouse IgG2a goat  1:100 (IHC, IF) Southern Biotech 
α-mouse IgG1 rabbit biotin 1:100 (IHC, IF) Zymed 
α-mouse IgG2a rabbit biotin 1:70 (IHC, IF) Zymed 
α-mouse IgG3 sheep  1:100 (IHC, IF) Serotec 
α-mouse IgG1 sheep  1:250 (IHC, IF) Binding Site 
α-mouse IgG2b sheep  1:500 (IHC, IF) Binding Site 
α-rabbit IgG goat Biotin 1:200 (IHC, IF) Jackson ImmunoResearch 
α-mouse goat Atto 633 1:500 (IF) Sigma-Aldrich 
α-sheep donkey Cy2 1:50 (IF) Jackson ImmunoResearch 
α-sheep donkey Cy3 1:800 (IF) Jackson ImmunoResearch 
 
Flow, flow cytometry; IF, immunofuorescence; IHC, immunohistochemistry; WB, western blot 
  
3.1.2 Kits 
Table 3. Kits used in this work. 
Name Source 
ABC-AP Kit Vector Laboratories 
Alexa Fluor Antibody Labeling Kit Invitrogen 
CD4 T cell isolation Kit (untouched) Miltenyi Biotec 
BDCA4 Microbead Kit Miltenyi Biotec 
Cytofix/ Cytoperm Kit Beckton Dickinson 
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DNeasy Blood&Tissue Kit Qiagen 
Human/ mouse T cell Nucleofection Kit AMAXA Lonza 
Nucleobond Maxi prep Kit PC500 Macherey-Nagel 
 
3.1.3 Chemicals and consumables 
Table 4. Chemicals and consumables. 
Name Source 
Acrylamide bis aqueous solution/Rotiphorese Gel 40 Roth 
Ammoniumpersulfate (APS) Roth 
Ampicillin Roth 
AutoMACS column Miltenyi Biotec 
Blotting paper (Whatman 3MM) Schleicher & Schuell 
Bovine serum albumin (BSA), fraction V Roth 
Bovine serum albumin (BSA)-c Aurion 
BD Phosflow™ Fix Buffer I BD Biosciences 
BD Phosflow™ Perm Buffer III BD Biosciences 
Calcium chloride Merck 
p-Coumaric acid Sigma-Aldrich 
Cell strainer (40 μm/ 100 μm) nylon BD Falcon 
Cell culture consumables (flasks, plates, dishes) BD Falcon 
Citrate buffer (pH 6.1/9.0) Dako 
Citrate buffer pH 9 (Concentrate) Dako 
Coverslips 12 mm Marienfeld 
Di-methylsulfoxid (DMSO) Merck 
Di-potassiumhydrogenphosphate (K2HPO4) Roth 
Di-sodiumhydrogenphosphate (Na2HPO4) Roth 
EBSS (Earle`s balanced salt solution) 10x Sigma-Aldrich 
EBSS (Earle`s balanced salt solution) 10x Gibco 
ELISA plates Maxi sorb (96 well) Nunc 
Ethanol ROTIPURAN®  ≥99,8 %, p.a.  Roth 
Ethidium bromide Merck 
Fetal calf serum (FCS) Biochrom 
Ficoll Biochrom 
Fungizone Invitrogen 
Glycine Roth 
Hematoxylin Sigma-Aldrich 
Hematoxylin, Mayer's Dako 
Hoechst staining dye Invitrogen 
Human AB serum (Lot: 27240 #34005100) Invitrogen 
Hydrogen peroxide (H2O2) Merck 
Isopropanol Sigma-Aldrich 
Interferon α (6,000 IU/μl) Roche 
Interleukin 2 (IL2) human recombinant Biomol 
Interleukin 3 (IL3) human recombinant Invitrogen 
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Immun-Blot® PVDF Membrane Bio Rad 
Kanamycin Roth 
Levamisol Sigma-Aldrich 
Luminol Sigma-Aldrich 
Lipopolysaccharides from Escherichia coli (LPS)  Sigma-Aldrich 
β-Mercaptoethanol Sigma-Aldrich 
Midori Green DNA dye Nippon Genetics 
Milk powder Roth 
Mini-PROTEAN® TGX™ Precast Gels Bio Rad 
Harleco Mounting medium (Aquatex®)  Voigt Global Distribution 
Fluoroshield™ with DAPI (histology mounting medium) Dako 
Mowiol Calbiochem  
N-actetyl-D-mannosamine Sigma-Aldrich 
N-actetyl-D-mannosamine Werner Reutter 
N-butanoyl-D-mannosamine Werner Reutter 
N-cyclopropylcarbamyl-D-mannosamine Werner Reutter 
N-isobutanoyl-D-mannosamine Werner Reutter 
N-pentanoyl-D-mannosamine Werner Reutter 
N-propanoyl-D-mannosamine Werner Reutter 
New Fuchsin Sigma-Aldrich 
Nitrocellulose membrane, Whatman GE Healthcare 
Non-essential amino acids, solution (100x) Invitrogen 
Paraformaldehyd (PFA) Roth 
Pancoll human density 1,077 g/l PanBiotech 
Biocoll  Biochrom 
Penicillin/ Streptomycin Sigma-Aldrich 
peracetylated N-actetyl-D-mannosamine Werner Reutter 
peracetylated N-glycolyl-D-mannosamine Ronald L Schnaar 
peracetylated N-propanoyl-D-mannosamine Werner Reutter 
Lectin from Phaseolus vulgaris (PHA) Sigma-Aldrich 
Phorbol-12-Myristate-13-Acetate (PMA) Merck 
Poly-L-Lysin Sigma-Aldrich 
Potassiumchloride (KCl) Merck 
Potassium-di-hydrogenphosphate (KH2PO4) Roth 
Saponin Roth 
Saponin Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Serva Electrophoresis 
Sodium pyruvate solution (100x) Invitrogen 
Sucrose Sigma-Aldrich 
Reagent reservoirs Thermo Scientific 
Target Retrieval Solution (Concentrate) Dako 
TaqMan Universal Master Mix; #4304437 Applied Biosystems 
TEMED (N, N, N, N-Tetramethylethylendiamin) Roth 
Tris (Trishydroxymethylaminomethan) Roth 
Triton X-100 Pharmacia Biotech 
Trypsin-EDTA (0.25%) Biochrom 
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Trypan blue Invitrogen 
V-bottom plates Corning 
Vitamins solution (100x) Invitrogen 
X-ray films, CL-Xposure clear blue Thermo Scientific 
Xylene (isomers)  >98 %, pure, for histology  Roth 
 
3.1.4 Laboratory equipment 
Table 5. Laboratory equipment. 
Name Source 
Balance Ohaus Explorer Ohaus, Nänikon 
Blotter Fastblot B43/ B44 Biometra 
Centrifuge Biofuge fresco Heraeus 
Centrifuge HERAEUS Megafuge 40R Thermo-Scientific 
Electrophoresis chamber Mini-PROTEAN® Tetra Cell Bio Rad 
ELISA reader multiscan EX Thermo-Labsystems 
Flow cytometer FACSCalibur Beckton Dickinson 
Flow cytometer FACSCanto Beckton Dickinson 
Flow cytometer FACSVerse Beckton Dickinson 
Fluorescence microscope IX70 Olympus 
Fluorescence microscope Eclipse Ti-S Nikon 
Incubator HERAcell 150i  Thermo-Labsystems 
LSM510 confocal microscope Zeiss 
MagNA pure LC nucleic acid extractor Roche 
Nanophotometer Pearl Implen 
Spectrophotometer GENESYS 10S UV-VIS Thermo-Labsystems 
Nucleofection device AMAXA Lonza 
Pipettes Biopette A Labnet 
PIPETBOY® acu Pipet Aid INTEGRA Biosciences 
Polyacrylamide Gel Elektrophoresis (Minigel) Biometra 
Power supply PowerPac™ Basic Power Supply Bio Rad 
Shaking incubator HT Infors 
Sterile hood SterilGard III Advance The Baker Company 
Sterile hood MSC-Advantage  Thermo-Scientific 
Table centrifuge Multifuge 3S-R Heraeus  
Table centrifuge MicroSTAR Thermo-Scientific 
Trans-Blot® Turbo™ Transfer System Bio Rad 
 
 
 
 
 
   3 MATERIAL AND METHODS 
22 
 
3.1.5 Buffers and solutions  
Table 6. Buffers and solutions recipes. 
Blocking and antibody dilution buffer for fluorescence microscopy  
PBS 1x  
FCS 5 % (v/v) 
BSA-c 0.1 % (v/v) 
Horse serum 2-10 % (v/v) 
   
Calcium chloride (CaCl2) 10x  
CaCl2 2.5 mM 
in H2O  
sterile filtration  
   
EBSS washing buffer   
10x EBSS (Earle`s balanced salt solution)  100 mL 
Hepes (1 M)  10 mL 
add dH2O  1 L 
adjust to pH pH 7.4  
BSA (0.2%) 2 mL 
   
EBSS saponin buffer  
EBSS washing buffer  
Saponin  0.1% (w/v) 
   
Flow-stain buffer  
PBS 1x  
FCS 2 % (v/v) 
   
HBS buffer (2x)   
NaCl  280 mM 
Hepes  50 mM 
Na2HPO4 x 2H2O  1.5 mM 
in H2O   
pH 7.1  
   
MACS running buffer  
PBS 1x  
Bovine serum albumin (BSA)  0.5% (w/v) 
EDTA  2 mM 
pH 7.2  
  
Orange G loading dye (5x)  
Orange G  20 mg 
Sucrose 2 g 
dH2O 5 mL 
   
10x PBS (Phosphate-buffered saline)  
NaCl  96 mM 
Na2HPO4 x 2H2O  10 mM 
Na2H2PO4 x H2O  2.3 mM 
in H2O  
pH 7.4  
   
PBS-Tween buffer  
PBS 1x  
Tween-20   0.1 % (v/v) 
   
Paraformaldehyde (PFA) 4%  
Paraformaldehyde  4 % (w/v) 
in 1x PBS  
pH 7.2  
   
SDS-PAGE sample buffer (2x)  
Tris/HCl pH 6.8  130 mM 
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3.1.6 Drugs and inhibitors 
Table 7. Drugs and inhibitors used in this work. 
Name Source 
ALLN Calbiochem  
Azidothymidine (AZT) Sigma-Aldrich 
Bafilomycin A1 Sigma-Aldrich 
Brefeldin A Sigma-Aldrich 
Chloroquine Sigma-Aldrich 
Efavirenz (EFV), Sustiva 30 mg/ml Bristol-Myers Squibb 
Human interferon alpha Roche 
Murine interferon alpha Pbl Interferon Source 
Z-Leu-Leu-Leu-al (MG132) Sigma-Aldrich 
 
 
SDS 6 % (w/v) 
Glycerol  10 % (v/v) 
β-Mercatoethanol  10 % (v/v) 
Bromphenole blue  tip of spatula 
   
SDS-PAGE running buffer  
Tris/HCl  250 mM 
SDS  0.1 % (w/v) 
Glycin  200 mM 
   
SDS-PAGE low separating gel buffer  
Tris/HCl pH 8.0  1.88 M 
   
SDS-PAGE stacking gel buffer  
Tris/HCl pH 6.8  0.65 M 
   
SG-PERT buffers  
Preparation and storage of SG-PERT assay buffers: see Pizzato et al. 2009  
   
TBS (Tris-buffered saline)  
Tris  50 mM 
NaCl  150 mM 
  
Tris-EDTA (TE) buffer   
Tris 10 mM 
pH 8.0  
EDTA 1 mM 
   
Tris-acetate-EDTA (TAE) buffer 50x  
Tris 2 M 
Acetic acid 2 M 
EDTA 50 mM 
pH 8.3  
  
Western Blot transfer buffer  
Tris/HCl pH 8.8  25 mM 
Glycin 192 mM 
Methanol  20 % (v/v) 
SDS 0.05 % (w/v) 
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3.1.7  Markers and standards 
Table 8. DNA and protein markers/standards used in this work. 
Name Source 
DNA Smart Ladder Eurogentec 
Spectra™ Multicolor Broad Range Protein Ladder MBI-Fermentas 
Precision Plus Protein™ All Blue Standards Bio Rad 
 
3.1.8  Media  
Table 9. Media for bacteria. 
Lysogeny broth (LB) medium and agar  
NaCl  5 g/L 
Yeast extract 5 g/L 
Tryptone 10 g/L 
add H2O  
pH 7.2  
for plating: add Agar agar  12.5 g/L 
Autoclave  
antibiotics were added to a final concentration of 0.1 mg/mL  
  
Terrific broth (TB) medium  
Yeast extract 24 g 
Tryptone  12 g 
Glycerol 4 mL 
dH2O  add 900 mL 
autoclave and cool down to < 60°C, then mix with sterile:  
KH2PO4 2.31 g 
K2HPO4 12.5 g 
dH2O  add 100 mL 
antibiotics were added to a final concentration of 0.1 mg/mL  
 
Table 10. Media for eukaryote cells 
Media for cell culture  
RPMI 1640+ GlutaMAX or DMEM high (4500 mg/l glucose)  
(Gibco) complemented with:  
 
FCS (heat inactivated) 10 % (v/v) 
Penicillin  50 U/ml 
Streptomycin 50 μg/ml 
  
Human lymphoid aggregate culture (HLAC) medium  
RPMI 1640+ GlutaMAX complemented with  
FCS (heat inactivated) 15 % (v/v) 
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Fungizone 1 % (v/v) 
Penicillin 50 U/ml 
Streptomycin 50 μg/ml 
Non-essential amino acids 1 % (v/v) 
Sodium pyruvate  1 % (v/v) 
  
Freezing medium  
DMEM high (4500 mg/l glucose) complemented with  
FCS (heat-inactivated) 30 % (v/v) 
DMSO 10 % (v/v) 
  
Generation of L929 supernatant  
Thaw and expand L929 cells for a week in RPMI (+FCS, +Penicillin/Streptomycin)  
After one week: start collecting supernatant (collect at least 1 liter in total)  
During collection: Split cells 1:2 every second day and havest supernatant  
Discard cells after 4 weeks  
Sterile filter collected supernatant (0.22 μM)  
Titer activity and determine BMDM purity by flow cytometry  
 
3.1.9  Bacterial strains 
Table 11. Bacterial strains used in this work. 
Strain Characteristics Genotype Utilized for 
Stable II               
(E.coli)    
High transformation 
efficiencies; low 
recombination rates 
F- mcrA Δ(mcrBChsdRMSmrr) recA1 endA1 lon 
gyrA 96 thi supE44 relA1 λ-Δ(lac-proAB) 
Proviral plasmid 
transformation and 
amplification 
3.1.10  Cell lines 
Table 12. Cell lines used in this work. 
Name Characteristics/ phenotype Medium 
293T Human embryonic kidney cell line expressing the large T antigen of SV40 (Pear et al., 1993); 
ATCC no.: CRL-11268 
DMEM 
ANA-1 Established from bone marrow cells of C57BL/6 (H-2b) mice (Blasi et al., 1985) RPMI1640 
Jurkat Human T lymphocyte cell line derived from an acute T cell leukemia; ATCC no.: TIB-152 RPMI1640 
L929 NCTC clone 929, subcutaneous areolar and adipose tissue of a 100-day-old male C3H/An 
mouse, secrete M-CSF 
RPMI1640 
S1A.TB Balb/c strain derived mouse T lymphocyte cell line. Derived from the S1A lymphoma. ATCC 
No.: TIB-27 
DMEM 
TZM-bl HeLa-derived indicator cell line (Wei et al., 2002) DMEM 
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3.1.11  Plasmids 
Table 13. Plasmids used in this work.  
Plasmid name Reference Received from/ Generated by 
pMoMLV-GFP Diss. Volker Herrmann, Goffinet et al., 2007 H.-G. Kräusslich 
FL-MLV-GagGFP pLRB303 Jin et al., 2011 W. Mothes 
 
3.1.12  Primers 
Table 14. Primers used for genotyping of wild-type and Siglec-1 knockout mice. 
Name Sequence 
Neo CGTTGGCTACCCGTGATATTGC 
SND1F3 CACCACGGTCACTGTGACAA 
SND2R2 GGCCATATGTAGGGTCGTCT 
 
3.1.13  Computer software 
Table 15. Computer software used in this work. 
Software Source 
Accelrys Draw 4.2 Biovia 
Adobe Illustrator CS6 Adobe 
Adobe Photoshop CS6 Adobe 
Aperio ImageScope software Leica Biosystems 
Ascent Software 2.6 Thermo Labsystems 
CellquestPro Beckton Dickinson 
Endnote X5 ISI Research software 
FACS SUITE software Beckton Dickinson 
FlowJo X Tree Star, Inc. 
LSM5 software Zeiss 
Microsoft Office 2010 Microsoft Cor. 
Odyssey 2.1 Li-cor Biosciences 
GraphPad Prism version 6.00 for Windows GraphPad software 
Image Lab software Bio Rad 
Bio Rad CFX Manager Software Bio Rad 
Nikon NIS Elements software Nikon 
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3.2 METHODS 
3.2.1 Molecular biology 
3.2.1.1 Transformation of bacteria  
25 μl of competent bacteria (Stable II cells) were transformed by addition of 1 μg plasmid DNA. After 
20 minutes of incubation on ice, bacteria were subjected to heat shock at 42 °C for 1 minute and then 
cooled down on ice for 2 minutes. After 30 minutes to 1 hour incubation in 1 ml LB-medium at 37 °C, 
bacteria were plated on LB-agar plates containing ampicillin overnight at 37 °C. 
 
3.2.1.2 Large scale DNA preparation “maxi-prep” 
200 mL of overnight-cultured E. coli was pelleted by centrifugation (10 min, 4000 rpm, 4°C) and 
plasmid DNA was then isolated and purified according to the principle of anion exchange 
chromatography, using the NucleoBond MaxiPrep PC500 kit (Macherey Nagel) according to the 
manufacturer’s description. Plasmid DNA was then precipitated with isopropanol and washed with 
70% EtOH. Finally, DNA pellets were resuspended in 100-200 μl TE buffer. 
  
3.2.1.3 Quantification of DNA using spectrophotometry 
DNA concentrations were measured by UV-absorption spectrophotometry at a wavelength of 260 nm. 
Since the absorption is highest for proteins at 280 nm, the ratio of absorbance at 260 and 280 nm 
(A260/A280) can be used as an indicator of nucleic acid purity. This ratio will hence be reduced the 
more contaminating protein the sample contains. DNA was considered as pure at A260/A280 ratios 
ranging between 1.8 and 2.0. DNA solutions were generally adjusted to a concentration of 1 μg/μl and 
stored at -20°C or at 4°C. 
         
3.2.1.4 Agarose gel electrophoresis 
DNA fragments can be separated according to their size by agarose gel electrophoresis. For gel 
preparation, the agarose (1-2%) was dissolved in 1xTAE buffer by boiling for 2-5 minutes. After 
cooling down to below 60°C, the DNA dye Midori Green (Nippon Genetics) was added to the gel mix. 
Typically, before loading samples onto a gel, 20 μl DNA solution was mixed with 5 μl 5x Orange G 
loading dye. Samples were then loaded into the pockets of the gel that was placed in 1xTAE running 
buffer. Standard running conditions for a gel of the size 10x10 cm was 80 – 100 V. For size 
determination of DNA fragments, the DNA molecular weight marker “SmartLadder” (Eurogentec) 
was used. DNA band patterns were detected and documented by a BioRad ChemiDoc device equipped 
with UV- light (302 nm). 
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3.2.1.5 Genotyping of wild-type and Siglec-1 -/- mice 
DNA was prepared from tail cuts of newborn or infant (up to 3 weeks) mice using the DNeasy blood 
and tissue kit (Qiagen) according to manufacturer’s protocol for rodent tails. Following DNA 
extraction, a PCR reaction (3.2.1.6) was performed in order to amplify the DNA regions of interest. 
   
3.2.1.6 Polymerase chain reaction (PCR)  
For selective amplification of fragments from genomic mouse tail DNA, Taq polymerase was used 
according to the manufacturer’s protocol. PCR reactions were carried out in a final volume of 50 μl 
and contained the following components: autoclaved MilliQ water, x10 NEB buffer, 1.5 mM MgCl2, 
0.2 mM dNTPs, 1 μM of each sense and antisense primer, 0.025 U/μl NEB Taq and 1μl of the 
extracted template DNA. Amplification was performed using an Eppendorf thermocycler with the 
following settings:  
1. 95°C: 2 min   
2. 95°C: 30 sec (denaturation) 
3. 55°C: 30 sec (annealing) 
4. 72°C: 45 sec (elongation) 
5. Step 2 – 4 repeat x29 
6. 72°C: 5 min 
PCR products were separated and visualized by agarose gel electrophoresis. 
 
3.2.2 Cell biology 
3.2.2.1 Culturing and passaging of eukaryotic cell lines 
Cells were grown either in suspension or as monolayer cultures in culture flasks or on cell culture 
dishes in DMEM or RPMI (Gibco) complemented with supplements indicated in table 10. All cells 
were grown at 37°C, in 5% CO2 and 95% relative humidity in an incubator. Passaging was routinely 
performed 1-3 times a week (depending on the growth rate and confluence of the cell line) at a split 
ratio of 1:3 to 1:10. For adherent cells, the culture medium was aspirated and cells were rinsed once 
with sterile PBS. Cells were then incubated with a small volume of trypsin-EDTA for 5-10 minutes at 
room temperature or at 37°C. Medium containing FCS was used to resuspend dislodged cells, and a 
fraction of the cell suspension was transferred to a fresh cell culture flask or plate. Non-adherent 
suspension cells were generally cultivated at a density around 5x10
5
 cells/mL, in cell culture flasks 
standing in an upright position. 
      
3.2.2.2 Long-term storage and thawing of cells 
For long-term storage, cells were cryo-preserved in liquid nitrogen. Around 1x10
7
 cells were pelleted 
by centrifugation and resuspended in 500 μl freezing medium in cryotubes (Nunc). Cells were first 
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frozen and stored for 24 hours at -80 °C, before transfer to liquid nitrogen. For thawing, an aliquot of 
cells was thawed rapidly, washed once in cell cultivation medium and resuspended in an appropriate 
volume of fresh medium. 
 
3.2.2.3 Human peripheral blood 
Fresh human blood was obtained from healthy donors with informed consent and was approved by the 
Local Ethics committee of the Medical Faculty of the University of Heidelberg (approval no. 
157/2006). Peripheral mononuclear cells (PBMC) were separated from whole blood by density 
gradient centrifugation (Biocoll, Biochrom). For lymphocyte and T cell cultures, cells were maintained 
in complete RPMI, at a density of 2x10
6
 cells/mL. In case of T cell activation, PHA-P (5 μg/mL) or 
PHA-L (2 μg/mL) (both from Sigma-Aldrich) were added to the culture medium for 2-3 days together 
with IL-2 (20 or 100 IU/mL) (Biomol). 
 
3.2.2.4 Human tonsil tissue 
Fresh tonsil tissue was obtained from routine tonsillectomies performed at the department of 
Otolaryngology, Head and Neck Surgery, University of Heidelberg. The use of anonymous surgical 
waste was approved by Heidelberg University’s ethics committee (approval no. 077/2005). 
Immediately after tonsillectomy, tonsils were cut in 1-3 mm pieces and gently passed through a 100 
μm cell strainer (BD) into a cell culture dish filled with HLAC medium. Cells were separated on a 
Ficoll gradient. Lymphocytes were collected and washed twice in PBS and thereafter either stained for 
analysis by flow cytometry or cultivated in 96-well round-bottom plates, seeded at 1x10
6
 cells per well 
in 200 μl of HLAC medium. 
 
3.2.2.5 Primary mouse cells 
Bone marrow derived macrophages (BMDM) were prepared from C57BL/6 mice. After sacrifice 
using CO2, femur and tibia were extracted and bone marrow cells collected by centrifugation. Cells 
were seeded in a 15 cm tissue-culture dish containing complete RPMI and incubated at 37°C over-
night. The following day, suspension cells were pelleted, resuspended and counted. 10x10
6
 cells per 
10 cm bacterial petri dish were then seeded in L929-containing BMDM-differentiation medium. 3 
days later, L929 supernatant was added to the cultures. Cells were typically harvested and reseeded for 
experiments 6 days after preparation. For some experiments, IFNα (pbl Interferon source) was added, 
either to the differentiation cultures at day 4 of differentiation or at day 6 when reseeding the cells for 
an experiment. 
Spleen and lymph nodes were collected from euthanized C57BL/6 mice. Organs were collected in cold 
RPMI and gently passed through a 100 μm cell strainer. Cell suspensions were then washed once in 
PBS, resuspended in complete RPMI, counted and seeded either in a tissue-culture flask or plate for 
the appropriate volume. Cells were typically seeded at a density of 2-5x10
6
 cells/mL. In case of B- or 
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T cell activation 7.5 μg/mL LPS (Sigma-Aldrich) or 10 nM phorbol myristate acetate (PMA, 
Calbiochem) respectively, was added to the cultures. 
 
3.2.3 Virological methods 
3.2.3.1 Calcium phosphate precipitation for MLV production 
293T cells were transfected by calcium phosphate precipitation. For virus production 4-6x10
6
 cells 
were seeded in a 15 cm dish the day before transfection. 40-70 μg DNA was used per dish. DNA was 
mixed with H2O (Braun) and then 0.1 mL CaCl2 was added to the mixture. After vortexing, 1 mL HBS 
buffer was added dropwise. The solution was vortexed again and then incubated at room temperature 
before dropwise addition to the 293T cells seeded the day before. Medium was exchanged 4-6 hours 
post transfection and around 40 hours later, supernatants were collected and used for concentration and 
purification. 
 
3.2.3.2 Production of MLV under treatment with ManN-analogs  
293T cells were seeded for virus production in the presence or absence of ManN analogs at sub-toxic 
concentrations (5 mM ManNAc, -Prop, -But, -iBut, -Pent, -Cyclo or 0.3 mM peracetylated (–PA) 
ManNGc, -Ac, -Prop). After 5 days, cells were re-seeded and transfected with MLV-GFP plasmid 
using the calcium phosphate precipitation method (3.2.3.1). 4-6 hours post transfection the medium 
was changed and new ManN analogs added. 48 hours post transfection, MLV particles were harvested 
by ultracentrifugation through a 20% sucrose cushion. After freezing at -80°C, viral titers were 
determined by direct infection of S1A.TB cells. 
 
3.2.3.3 Determination of viral infectivity  
The infectivity of MLV-GFP stocks encoding a gene for GFP expression was generally analyzed by 
flow cytometry. Thus, the cell line S1AT.B (which was typically used as MLV target cells in the 
experiments in this thesis) was infected with serial dilutions of the generated virus stocks and 
incubated for 48 hours. Cells were then analyzed by flow cytometry for GFP expression. The 
infectious titer (IU/ml) of the respective virus stock was calculated using the percentage of GFP-
positive cells. 
 
3.2.3.4 MLV capture and transfer assays   
To assess Siglec1-dependent MLV transfer from macrophages to lymphocytes, L929-differentiated 
BMDM were exposed to – i.e. pulsed with – MLV-GFP for 4 hours at 37°C, and then washed 
extensively in PBS (in case of antibody blocking, BMDM were treated with 10 μg/mL anti-mSiglec1 
or isotype control antibody for 30 minutes at 4°C before virus pulse). The mouse T cell line S1A.TB 
was then added and co-cultured with the macrophages for 48 hours. T cells were harvested and 
analyzed for GFP-expression on a flow cytometer. MLV capture experiments were performed 
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acording to the description above, with the difference that the pulsed BMDM were harvested 
immediately after the extensive post pulse wash. BMDM from MLV capture assay were either 
subjected to flow cytometry or to RT-PCR. 
  
3.2.3.5 SYBR Green-based Product Enhanced Reverse Transcriptase (SG-PERT) assay 
SG-Pert is an assay for quantitation of retroviruses in cell culture supernatants and has been described 
by M. Pizzato and colleagues (162). Briefly, the enzymatic activity of Reverse Transcriptase (RT), 
present in all retroviruses, is measured using an RNA template derived from the bacteriophage MS2, 
which is reverse transcribed in vitro by the retroviral enzyme. The resulting DNA product (cDNA) is 
then amplified by PCR and quantified using the signal obtained from the intercalating fluorescent dye 
SYBRGreen, as a measure of the amount of virions present in the sample. The linear logarithmic 
relationship between virus concentration and CQ (crossing point) value, where an increase in virus 
concentration of 1 log corresponds to a difference of 3.3 in CQ values, is described by Pizzato et al 
(162).  
In short, the reaction was carried out as follows: 10 μl of the diluted cell/virus lysate samples were 
mixed immediately with 10 μl of 2× reaction mix already aliquoted into a white shell clear well plate 
with a seal (BioRad). The plate was briefly centrifuged to sediment the reaction components and then 
applied to the BioRad real-time platform. Thermal cycler conditions used were: 20 minutes RT 
reaction at 42°C, 2 minutes hot-start Taq activation at 95°C and 40 cycles of amplification. Each 
amplification cycle was composed of 5 seconds denaturation at 95°C, 5 seconds annealing at 60°C, 15 
seconds of elongation at 72°C and 7 seconds of acquisition at 80°C.  
Biological triplicate samples were run in technical triplicates (in total 3x3 replicates). The relative RT 
activity was calculated by normalizing samples to the positive control sample within each data set. 
 
3.2.4 Standard laboratory methods 
3.2.4.1 Flow Cytometry 
For all flow cytometry experiments, at least 2x10
5
 cells/sample were used. For GFP readout, cells 
were washed once in PBS, followed by flow cytometric analysis (FACS Calibur or FACS Verse, BD 
Bioscience). Data was analyzed with FlowJo software (TreeStar). Cells were gated on forward scatter / 
side scatter characteristics. For surface antigen labeling, cells were transferred to a 96-well V-bottom 
plate, washed once in flow-stain buffer and incubated with primary antibodies or directly labeled 
antibodies diluted in flow-stain buffer for 30 minutes at 4°C. Washing was followed by flow 
cytometric analysis. For intracellular labeling, cells were surface labelled, fixed, permeabilized and 
stained either according to the BD Cytofix/Cytoperm protocol or to the BD Phosflow protocol for 
staining of nuclear antigens. 
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3.2.4.2 Immunofluorescence and microscopy of adherent or suspension cells 
Adherent cells were seeded onto glass coverslips (12 mm) one day before the experiment (e.g. virus 
pulse), while suspension cells were seeded on coverslips that were either coated with Poly-L-lysine or 
left uncoated, for 20-30 minutes at 37°C. Prior to staining, cells were fixed in 4% paraformaldehyde 
(PFA) for 15-30 minutes, permeabilized either with 0.1% Triton X-100/PBS for 2-4 minutes (BMDM) 
or with PBS supplemented with 0.5% saponin (Sigma-Aldrich). Cells were then blocked for 20 
minutes in PBS containing 5% FCS, 0.1% BSA-c (Aurion), and 2-10% horse serum (Sigma-Aldrich). 
Cells were incubated with primary antibodies diluted in blocking buffer for 60 minutes at room 
temperature, then fluorescently conjugated secondary antibodies for 60 minutes, with washes in 
blocking buffer in between. Coverslips were mounted onto glass slides using DAPI mounting medium 
(Sigma). Epifluorescence images were taken on an inverted Nikon eclipse Ti-S microscope using the 
Nikon software program, on an Olympus IX71 inverted microscope and confocal images on a Leica 
SP5. The final presented images were prepared using ImageJ or/and Adobe Photoshop CS5. 
 
3.2.4.3 Real-Time Polymerase chain reaction (RT-PCR)  
To normalize the data obtained with the SG-PERT assay for cell numbers, a quantitative PCR of 
genomic DNA was performed, using a probe for the murine GAPDH housekeeping gene. After DNA 
extraction from BMDM cell pellets using an automated MagNAPure LC nucleic acid extraction 
instrument (Roche), a commercial 20x mix containing primers and probe (6-carboxyfluorescein 
(FAM)- labelled) was used to detect GAPDH DNA. After preparation of a master mix containing (per 
sample) 1.25 μl commercial GAPDH mix, 8.75 μl H2O and 12.5 μl TaqMan Mix, this mix was 
aliquoted into an optical plastic 96-well microtiter plate (Applied Biosciences) in a volume of 22.5 
μl/sample. 2.5 μl of sample DNA was then added to each well.    
The PCR was performed at an ABI7500 under the following conditions:    
1. 50°C: 2 min   
2. 95°C: 10 min 
3. 95°C: 15 sec (denaturation) 
4. 60°C: 1 min (annealing) 
5. Step 1 – 4 repeat x39 
Data was analyzed using the ABI7500 v.2.0.1 software. 
 
3.2.4.4 SDS-Polyacrylamide-Gel electrophoresis (SDS-PAGE) 
For protein analysis, samples were mixed with 2x SDS-PAGE sample buffer and denaturated at 95°C 
for 5 minutes and loaded onto precast 10-12% polyacrylamide gels (BioRad). Gels were typically run 
at 80 mA per gel for around 30 minutes. For estimation of the molecular weight of the samples, a 
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prestained protein marker was used as reference. Proteins were then further processed for western-blot 
analysis. 
 
3.2.4.5 Immunoblot analysis 
After separation by SDS-PAGE, proteins were electro-transferred onto polyvinylidene difluorid (PVD) 
membranes. After 30 minutes membrane blocking in 5% non-fat milk, membranes were incubated 
with primary antibodies diluted in a 2% BSA/TBS buffer over-night at 4°C. After extensive washing 
in TBS, secondary horse radish peroxidase-conjugated antibodies were added and incubated with the 
membranes for 1 hour at room temperature. Membranes were developed using the Clarity western 
ECL development kit (BioRad) and chemiluminescent bands were visualized and documented with a 
BioRad ChemiDoc device. 
 
3.2.4.6 Immunohistochemistry and microscopy of tissue sections and tissue micro array 
(TMA) 
Paraffin-embedded tissue sections, anonymously obtained from routine diagnostics (Institute for 
Pathology Heidelberg and the Senckenberg Institute of Pathology, Frankfurt), were 
immunohistochemically stained according to the following description: After deparaffinization in 
xylene (2 x 5 minutes), and hydration in ethanol (100% 2 x 5 minutes, 96% 3 minutes, 70% 3 
minutes), sections were first rinsed in dH2O and then steam cooked for antigen retrieval in pre-heated 
10 mM citrate buffer (pH 6.1, DAKO) for 30 minutes. Slides were then removed from the steamer and 
cooled down on ice for 15-30 minutes. After washing slides in dH2O (2 x 2 minutes) and in a pH 7.4 
washing buffer containing H2O with 10% Earle’s balanced salt solution, 1% Hepes and 0.2% bovine 
serum albumin (EBSS/H/BSA) (3 x 2 minutes), sections were permeabilized for 15 minutes in 
EBSS/H/BSA washing buffer with 0.1% saponin added (EBSS/H/BSA/SAPONIN). Tissue sections 
were then incubated with a total volume of 100 μl/slide of primary antibody solutions (antibody 
dilutions were prepared in EBSS/H/BSA/SAPONIN buffer) at room temperature for one hour and then 
overnight at 4°C. The following day, sections were washed in EBSS/H/BSA/SAPONIN (3 x 2 
minutes) and blocked by incubation for 20 minutes at room temperature with sheep or donkey serum 
(dilution 1:6), depending on which species the secondary antibody was from. A secondary, 
biotinylated antibody (also diluted in EBSS/H/BSA/SAPONIN buffer) was then added, and after 
incubation for 30 minutes at room temperature, tissue secions were washed three times and incubated 
with an avidin-biotin alkaline phosphatase solution (ABC-AP-kit) (Vectastain) for 30 minutes. Finally, 
slides were washed three times in EBSS/H/BSA/SAPONIN, twice in EBSS/H/BSA and another two 
times in TBS and thereafter developed with New Fuchsin (Sigma) in the presence of levamisole 
(Sigma) for 1-20 minutes. The reaction was judged by eye and stopped with tap water. Slides were 
mounted with Harleco Aquatex mounting medium and analyzed with an Olympus BX45 or a Nikon 
eclipse Ti-S microscope.  
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The TMA was originally assembled by Dr. Judith Lehmann-Koch from the Department of Pathology, 
University of Heidelberg, and is courtesy of the Nationales Zentrum für Tumorerkrankungen (NCT 
Heidelberg). The array contained tissue sections from 250 patients with assessable clinical records. 10-
30 postmortem and biopsy tissues from each of 20 different organs had been paraffinized and mounted 
on glass slides. After immunohistochemical staining for detection of CD317 according to the above 
description, slides were scanned for image acquisition by John Moyers from the Department of 
Pathology, Heidelberg University. CD317 expression in different tissues was then evaluated together 
with Dr. Felix Lastischka, Department of Pathology, Heidelberg University, and rated according to its 
expression as – (negative), + (low), ++ (medium) or +++ (high). Images were acquired with Aperio 
ImageScope software. 
 
3.2.4.7 Immunofluorescence and microscopy of tissue sections 
Paraffin-embedded tissue sections were treated as described in section 3.2.4.7 on the first day of the 
staining procedure. The following day the primary antibody was washed off with 
EBSS/H/BSA/SAPONIN buffer three times, before the secondary antibody was applied and incubated 
with the tissue sections for 30 minutes (diluted in EBSS/H/BSA/SAPONIN buffer). After three more 
washing steps with EBSS/H/BSA/SAPONIN buffer, fluorochrome-coupled antibodies or conjugates 
were added to the slides (diluted in EBSS/H/BSA/SAPONIN buffer). Slides were incubated for 20-30 
minutes at room temperature in the dark and thereafter washed twice in EBSS/H/BSA/SAPONIN 
buffer, twice in EBSS/H/BSA buffer and twice in H2O. Slides were mounted with DAPI mounting 
medium (Sigma-Aldrich) and analyses were performed on an Olympus MT20 fluorescence 
microscope, a Leica AF6000 confocal microscope or a Nikon eclipse Ti-S microscope. 
 
3.2.4.8 Statistical analyses 
Plotting of graphs and general statistical analyses were performed using either Microsoft Excel or 
GraphPad Prism 5 software package (GraphPad Software Inc., La Jolla, CA). These two programs 
were also used to calculate significance values by applying the two-tailed, unpaired Student’s t-test. 
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4. RESULTS 
4.1 EXPRESSION PROFILE OF THE ANTIVIRAL RESTRICTION FACTOR AND TUMOR-
TARGETING ANTIGEN CD317/TETHERIN/HM1.24 IN HUMANS 
Many restriction factors including A3G, TRIM5α, SAMHD1 and MX2 act at early stages of HIV-1 
replication, whereas CD317/tetherin acts at a later stage. The importance of restriction factor activity 
in human cells can be seen by the fact that viruses have evolved countermeasures to overcome these 
barriers. The implications in disease progression and viral replication in vivo are often only poorly 
understood. To understand these, a detailed analysis of the expression profile is required, and was 
undertaken for CD317/tetherin in the present study. We perfomed microarray-based CD317 
expression profiling in nontransformed tissues to provide a framework for studies of its biological 
functions in humans, with a focus on its potential importance as an antiviral factor and on therapeutic 
strategies proposing CD317 as a target for immunotherapy of B-cell malignancies and solid tumors.  
The following chapter has been published during the course of this thesis and is modified from (I). 
 
CD317 Is Expressed on Specialized Cells in a Variety of Human Tissues 
As a methodological basis for a comprehensive evaluation of CD317 expression in vivo, we developed 
an immunohistochemical staining protocol for formalin-fixed, paraffin-embedded tissue sections, 
given that standard protocols yielded only low-level staining in tonsil (Fig. 4.1). The mouse anti- 
HM1.24 mAb, specific for an epitope in the extracellular domain of CD317 (114), was used as 
primary detection reagent. The specificity and sensitivity of this immunohistochemical staining 
protocol was validated on patient-derived multiple myeloma (71), tonsil tissue, and human cell lines 
expressing high endogenous CD317 levels (67) or no CD317 (153) (Figs. 4.2 and 4.3A).  
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Fig. 4.1 Optimization of an anti-CD317 immunohistochemistry protocol on human tonsil. Before immunostaining, 
sections from the formalin-fixed, paraffin embedded tonsil from one donor underwent various antigen retrieval protocols (a–d 
and a*–d*), details of which are reported in Materials and Methods. (a and a*) microwave and TBS buffer; (b and b*) 
microwave and EBSS buffer; (c and c*) steam cooker and TBS buffer; (d and d*) steam cooker and EBSS buffer. 
Subsequently, sections were stained with either the anti-HM1.24/CD317 mAb (IgG2a) (A) or a polyclonal rabbit anti-CD3 
antiserum (clone SP7) (B), followed by a biotinylated sheep α-mouse secondary antibody or donkey α-rabbit secondary 
antibody, respectively. Sections were then exposed to the avidin-containing ABC-AP Kit, followed by substrate development 
with New Fuchsin. Nuclei were counterstained with Hematoxylin. From (I). 
 
Fig. 4.2 Validation of the anti-CD317 immunohistochemistry protocol. (A) Patient-derived multiple myeloma and human 
cell lines, expressing either high levels of endogenous CD317 (mixture of TZM-bl and A3.01 cells) or no endogenous CD317 
(293T cells), were formalin-fixed and paraffin-embedded. Sections were stained with the anti-HM1.24 mAb (Left) or an 
IgG2a isotype control mAb (Right) using the optimized immunohistochemistry protocol, followed by a biotinylated sheep α-
mouse secondary antibody. Subsequently, sections were exposed to the avidin-containing ABC-AP Kit, followed by substrate 
development with New Fuchsin. Nuclei were counterstained with Hematoxylin. (B) Immediately after tonsillectomy, tonsil 
tissue was divided and either (i) snap-frozen in liquid nitrogen, cut on a cryotome, and fixed in ice-cold acetone (cryo 
section) or (ii) fixed in formalin and paraffin-embedded, sections of which underwent the antigen retrieval protocol (paraffin 
section). Staining of all sections was performed as described above. (Original magnifications, 10×–40×.) From (I). 
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Fig. 4.3 Detection of CD317 expression by three different antibodies. (A) Immunohistochemical detection of CD317 in 
tonsil. Sections from a paraffin block were stained either with the mouse anti-CD317 mAb clone 26F8 (IgG1; eBioscience), 
mouse anti-CD317 mAb clone HM1.24 (IgG2a; Chugai Pharmaceuticals), or corresponding isotype control mAbs (control, 
Right) using the optimized antigen retrieval protocol. (B) Western blot analysis of CD317 in homogenates from selected 
human tissues (liver, gallbladder, thyroid, and spleen) and cell lines with low (293T cells) or high (TZM-bl cells) endogenous 
CD317 expression. Cell lysates were separated by SDS/PAGE, and nitrocellulose membranes were probed with a polyclonal 
rabbit anti-BST-2 antiserum (provided by Klaus Strebel). From (I). 
 
In a cross-sectional CD317 expression analysis, we used a tissue microarray (TMA) containing 468 
individual sections derived from 25 paraffinized nontransformed tissue samples from more than 210 
patients. CD317 expression was rated based on a combined proportion and intensity scoring system 
reported by Allred et al (2). Remarkably, CD317 was expressed in more than 40% of patient samples 
in 21 of the tissues analyzed (Figs. 4.4 and 4.5A). The expression scores varied considerably among 
tissues; the highest scores were seen in spleen, gallbladder, and stomach (>70% medium or high 
expression scores), whereas more moderate expression scores were seen in pancreas, adrenal gland, 
small intestine, liver, and salivary gland (40–70% medium or high expression scores) (Fig. 4.5B). 
More than half of the cases analyzed for heart, ovary, uterus, kidney, testis, and bladder tissues 
received low or medium scores. CD317 expression in lung, appendix, skin, tonsil, fat, and thyroid 
samples of the TMA was low or negative (Figs. 4.4B, 4.4C and 4.5B).  
In a complementary approach, Western blot analyses of snap-frozen samples of tissues with high 
(liver, gallbladder, spleen) or low (thyroid) CD317 expression on immunohistochemistry (Figs. 4.4 
and 4.5) were confirmatory (Fig. 4.3B). Based on histological criteria, CD317 expression in organ 
sections of the TMA was identified on type I and type II pneumocytes in the lung, intercalated and 
striated ducts of major salivary glands, squamous epithelium of the esophagus, gastric fundic 
epithelium and glands, Paneth cells of the small intestine, mononuclear cells in the lamina propria of 
the large intestine, acinar cells of the exocrine pancreas, hepatocytes, gallbladder epithelium, cells in 
the adrenal zona reticularis, collecting ducts of the kidney, Leydig cells in the testis, endometrial 
anti-CD317 mAb (26F8)
anti-CD317 mAb (HM1.24)
Control
Control
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glands, and vasculature (Fig. 4A and 4.4C). Thus, in contrast to previous work (71), we found CD317 
to be widely expressed and exposed on a number of specialized cell types. 
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Fig. 4.4 CD317 is expressed in a variety of human tissues. (A, C) 20× magnification. (B) 40× magnification. TMA slides 
were stained with the anti-HM1.24/CD317 mAb (Left) or an isotype control mAb (Right), followed by a biotinylated sheep 
α-mouse secondary antibody. Subsequently, sections were exposed to the avidin-containing ABC-AP Kit, followed by 
substrate development with New Fuchsin. Nuclei were counterstained with Hematoxylin. From (I). 
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Fig. 4.5 Rating of CD317 expression in human tissues. The expression of CD317 detected in tissues of the TMA by 
immunohistochemistry was rated based on a proportion and intensity scoring system (22). (A) Histogram bars depict the 
percentage of samples (n = 6–34 per tissue), in which the indicated tissue section scored positive. (B) Histogram bars depict 
the percentage of samples with high (solid), medium (hatched), or low (open) expression ratings. The percentage of samples 
with negative ratings is not shown. From (I). 
 
CD317 Is Ubiquitously Expressed on Blood Vessels  
We next focused on the CD317 expression on vasculature. Blood vessels in all tissues represented in 
the TMA demonstrated CD317 staining in the lumen-oriented endothelial lining. In highly 
vascularized organs, such as spleen, the majority of CD317 expression was on blood vessels (Fig. 4.4 
and 4.6A), but prominent vessel staining was observed in sections from gastrointestinal tract, muscular 
tissue of the heart (Fig. 4.6C), liver, pancreas, and bladder as well (Fig. 4.6A). In line with these 
immunohistological findings, CD317 expression co-localized with expression of the blood vessel 
endothelial cell marker CD31 (platelet endothelial cell adhesion molecule, PECAM-1) in the 
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endothelium of larger arteries such as coronary arteries and the aorta, as well as in smaller, organ 
associated blood vessels such as those found in tonsil (Fig. 4.6B and D). We conclude that CD317 is 
highly expressed on blood vessels throughout the body. 
 
 
Fig. 4.6 CD317 is expressed on CD31+ blood vessel endothelium. (A, C) Immunohistochemical analysis of CD317 
expression on blood vessels in liver, bladder, pancreas, spleen, heart musculature and small intestine. Black arrows indicate 
blood vessels with CD317+ endothelium. (B, D) Co-expression analysis of the vascular endothelial cell marker CD31 
(PECAM-1) and CD317 in coronary artery, aorta, and tonsil tissue (two donors/organ). Tissue sections were labeled with the 
anti-CD31 mAb JC70A (IgG1) and the anti-HM1.24 mAb (IgG2a), followed by appropriate secondary reagents. Merged 
three-/two-color images for CD317 (red staining), CD31 (green staining), and nuclei (blue staining) are shown in B and in C, 
Right panel. Left and Middle panels show individual fluorescence channels. Fluorescent images were acquired at 10–60× 
magnification. Modified from (I). 
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Cell Type–Specific CD317 Expression in Hematopoietic Compartments and Intestinal 
Lamina Propria  
We next characterized CD317 expression in tonsil, peripheral blood mononuclear cells (PBMCs), and 
bone marrow. Based on documented CD317 expression on B cell malignancies, including multiple 
myeloma, plasma cell leukemia, and Waldenström’s macroglobulinemia (71) (Fig. 4.2A), we first 
focused on cells of the B-cell lineage. In tonsil, little or no expression of CD317 was found on naïve 
and immature B cells (soluble IgD+, CD21+), mature CD23+ B cells, or cells expressing the pan B-
cell marker CD19 (Fig. 4.7A). A considerable fraction of terminally differentiated CD138+ B cells, 
which localized primarily to the perifollicular region, stained positive for CD317 (Fig. 4.7A, white 
arrows). In tonsil, no CD317 expression was detected on T cells, tissue-resident macrophages, 
dendritic cells (Fig. 4.7B), or CD66b+ granulocytes. Expression analysis on PBMCs demonstrated that 
CD3+ T cells did not express CD317, whereas CD19+ B cells expressed low levels on their surfaces 
(Fig. 4.7C). CD14+ monocytes were the only cell type in peripheral blood that expressed high levels 
of CD317 (Fig. 4.7C). An initial expression analysis in a previous study (96) indicated preferential 
expression of CD317 on cell lines with characteristics of bone marrow stroma; based on this, the 
surface protein was termed bone marrow stromal antigen 2 (BST-2). In the present study, we assessed 
CD317 expression in bone marrow aspirates from healthy donors. A considerable fraction of nucleated 
bone marrow cells stained positive for CD317 by immunohistochemistry (Fig. 4.7D, Left). In Ficoll 
gradient–purified bone marrow, the majority of cells that expressed the stromal cell marker CD106 
(VCAM-1) (177) co-expressed CD317 on the surface (Fig. 4.7D). 
 
Fig. 4.7 Characterization of CD317 expression in tonsil, PBMCs, and bone marrow. (A) Co-expression analysis of 
CD317 and several markers of the B-cell lineage in human tonsil sections. (B) Co-expression analysis of CD317 (red 
staining) on dendritic cells, macrophages, and T cells (green stainings) in tonsil. (C) CD317 co-expression analysis on T 
cells, B cells, and monocytes in PBMCs by immunofluorescence microscopy of cells that had been seeded on coverslips, 
fixed, and permeabilized (Upper) or by flow cytometry of unfixed cells (Lower). FACS plots shown were gated on viable 
lymphocytes and monocytes. For microscopy, cells were stained with the anti-HM1.24 mAb, Alexa Fluor 660– labeled 
secondary Ab, and PE-conjugated Abs to the respective lineage markers. (Scale bar: 10 μm.) White arrows indicate double-
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positive cells. (D) CD317 immunohistochemistry of bone marrow. (Original magnification, 40×.) (Left) Co-expression 
analysis of the bone marrow stromal cell marker CD106 and CD317 in a bone marrow aspirate. Shown is the forward 
scatterplot/side scatterplot with the R1 live gate indicated and a FACS dot plot of CD106 and CD317. (Right) Relative 
percentages of CD317+ and CD317− cells among CD106+ cells. Data are representative of the results from two donors. 
From (I). 
 
Furthermore, co-labeling analyses of the lamina propria of the large intestine with cell type–specific 
markers identified CD138+ plasma cells, but not HIV target cells (i.e., CD4+ T cells, macrophages, 
DC), as the major CD317+ cell type (Fig. 4.8). These findings indicate that, along with terminally 
differentiated B cells (71), monocytes and primary bone marrow stromal cells express high levels of 
CD317 within the hematopoietic lineage. 
 
Fig. 4.8 Plasma cells, but not HIV target cells, in the lamina propria of the large intestine are CD317+. (A) 
Immunohistochemical analysis of CD317 expression in colon sections. (B) Co-expression analysis of CD317 (green staining) 
on DC-SIGN+ dendritic cells or CD68+ macrophages (red staining). White arrows indicate cells that express either CD317 or 
the cell type–specific marker. (C) CD317 co-expression analyses on CD3+ T cells, CD4+ cells, and CD138+ plasma cells on 
freshly isolated lamina propria lymphocytes by flow cytometry. Gate R1 defines the viable lymphocyte population. From (I). 
 
Expression of CD317 on Human Plasmacytoid Dendritic Cells Is Not Constitutive  
In mice, CD317 is a constitutively expressed surface antigen on plasmacytoid dendritic cells (pDC) 
(188) and a frequently used marker for positive selection of pDC from lymphatic organs. In human 
tonsil, BDCA2+ pDC were found predominantly in the T cell–rich lymphocyte wall and to a lesser 
extent in the perifollicular region (Fig. 4.9A, Left). Co-expression analysis of CD317 and BDCA2 by 
in situ immunofluorescence microscopy (Fig. 4.9A, Right) and flow cytometry (Fig. 4.9B) found no 
evidence of significant CD317 expression on pDC from human tonsil. Similarly, CD317 was not 
expressed on BDCA2+ pDC from Ficoll gradient–purified PBMCs, in line with a recent report (25). In 
isolated pDC, stimulation with type I IFNs upregulated CD317 mRNA levels by twofold to fivefold 
(Fig. 4.9C) and CD317 surface levels by threefold to fivefold (Fig. 4.9D). Collectively, these results 
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demonstrate a species-specific expression pattern of CD317 on pDC. In contrast to mice, CD317 is not 
constitutively expressed on pDC in human blood and tonsil, but can be up-regulated by type I IFNs, at 
least on isolated cells. 
 
Fig. 4.9 Expression of CD317 on pDC is not constitutive but can be stimulated in vitro by IFN-α or IFN-β. (A) 
Detection of BDCA2+ pDC in tonsil sections. GC, germinal center; LW, lymphocyte wall; PR, perifollicular region. Co-
expression analysis of CD317 on BDCA2+ pDC by (A, Right) in situ-double-immunofluoresence microscopy (A, Right) or 
flow cytometry of dispersed organs (B). (Scale bar in A: 10 μM.) In B, viable cells were identified by gating on the live 
lymphocyte population (gate R1) and analyzed for BDCA2 and CD317 expression (Right). (C) Relative CD317 mRNA 
levels in purified pDC from three donors were quantified by RT-PCR in unstimulated cells after exposure to IFN-β for 4 h. 
RNaseP-normalized CD317 mRNA levels in unstimulated pDC were set to 1. (D) pDC from peripheral blood were 
stimulated with IFN-α or IFN-β for 24 h and analyzed for surface CD317 expression on pDC by flow cytometry. From (I). 
 
Type I IFNs May Only Partially Regulate CD317 Expression In Vivo  
On various types of cultured cells, CD317 is up-regulated after exposure to type I IFNs (145, 198), 
consistent with its function as an antiviral restriction factor and the presence of IFN-response elements 
in the CD317 promoter (156). We examined the degree to which the prominent CD317 expression in 
certain cell types and tissues in vivo was induced by IFN. We began by performing co-labeling studies 
with the myxomavirus resistance protein A (MxA). The expression of MxA, which restricts the 
replication of orthomyxoviruses and other RNA viruses (85), is strictly dependent on stimulation by 
type I or type III IFNs, classifying MxA as a convenient marker for IFN bioactivity (202). Individual 
expression analyses of each restriction factor showed that the majority of MxA-expressing cells in 
tonsil were located within germinal centers, with additional cells staining positive in the lymphocyte 
wall and perifollicular region (Fig. 4.10A). In contrast, the majority of CD317+ cells were found in the 
perifollicular region, and few cells within germinal centers expressed CD317. Most importantly, 
double-immunofluorescence microscopy demonstrated that cells in tonsil typically expressed either 
A B
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MxA or CD317 (Fig. 4.10A, Lower and Fig. 4.11A), and that co-expression was a rare event (Fig. 
4.10A, Lower Right, white arrow). Similarly, CD317+ pneumocytes did not express the IFN 
biomarker MxA, and macrophages found in the lung were MxA+CD317− (Fig. 4.10B, Left and Fig. 
4.11B). In contrast, frequent co-expression of both restriction factors was found on vessel 
endothelium, as exemplified in aorta samples from several patients (Fig. 4.10B, Right and Fig. 4.11C).  
 
Fig. 4.10 Cell type–dependent coexpression of CD317 and the IFN biomarker MxA. (A) (Upper) Immunohistochemical 
detection of CD317 and MxA in tonsil. GC, germinal center; LW, lymphocyte wall; PR, perifollicular region. (Original 
magnification, 10×.) (Lower) Coexpression analysis of CD317 (red staining) and MxA (green staining) in tonsil by 
immunofluoresence microscopy. (Scale bars: Left, 100 μm; Right, 10 μm.) The white arrow indicates a coexpressing cell. (B) 
Coexpression analysis in lung tissue and aorta. Merged three-color images for CD317 (red staining), MxA (green staining), 
and nuclei (blue staining) are shown. Images from additional donors [tonsil (n = 2), aorta (n = 3), and lung tissue (n = 2)] are 
shown in Fig. 4.11. From (I). 
 
A
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Fig. 4.11 Coexpression analysis of CD317 and the IFN biomarker MxA in different human tissues from different donors by 
in situ immunofluorescence microscopy: tonsil (A), lung (B), and aorta (C). In B, arrows indicate MxA+ cells (green) or 
CD317+ cells (red). (C) (Right) Merged three-color images for CD317 (red staining), MxA (green staining), and nuclei (blue 
staining). (Left and Middle) Individual fluorescence channels from the identical image. Images from other donors are shown 
in Fig. 4.10. From (I). 
 
To explore whether exogenous IFN stimulation can trigger CD317 expression in tonsil explants, we 
exposed dispersed human lymphoid aggregate cultures (tonsil-HLAC;(104)) to IFN-α for 24 h. This ex 
vivo stimulation enhanced CD317 expression on tonsillar lymphocytes only marginally, whereas a 
strong and concentration-dependent increase of MxA expression was seen (Fig. 4.12A). As a 
reference, IFN-α also readily triggered surface expression of CD317 on Jurkat-TAg cells (Fig. 4.12B).  
 
 
Fig. 4.12 Primary lymphocytes from tonsil are largely refractory to IFN-α induction of CD317. Ex vivo HLAC cultures 
from tonsil (tonsil-HLAC) (A) and the T cell line Jurkat-TAg (B) were cultivated for 24 h in the absence or presence of the 
indicated concentrations of IFN-α and then analyzed for CD317 surface expression by flow cytometry. The mean 
A
B
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fluorescence intensity (MFI) of CD317 expression on viable lymphocytes from five donors was quantified; values are 
arithmetic mean ± SEM. (A, Lower) In parallel, lysates from IFN-α–stimulated HLAC were separated by SDS/PAGE and 
blotted for MxA. ERK levels served as a loading control. Shown are Western blots from one representative donor. From (I). 
 
Collectively, these results suggest a cell type– and/or tissue related IFN dependence of CD317 
expression. Whereas marked CD317–MxA coexpression was found in vessel endothelium, their nearly 
mutually exclusive expression pattern in lymphoid and pulmonary tissue and insensitivity to 
exogenous IFN stimulation suggest that type I IFNs may only partially regulate CD317 levels in vivo. 
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4.2 INVESTIGATING THE ANTIVIRAL ACTIVITY OF SAMHD1 IN RESTING T CELLS BY 
FLOW CYTOMETRY  
Resting CD4+ T cells are unlike activated CD4+ T cells refractory to productive HIV-1 infection and 
only become permissive upon activation (185, 214). Briefly, the activation process that resting T cells 
undergo – leading to proliferation – involves first a transition from the quiescent G0 state of the cell 
cycle into the G1 phase, which occurs after stimulation through the T cell receptor (TCR) (33). This 
event leads to production and secretion of interleukin-2 (IL-2) and the expression of IL-2-receptors on 
the cell surface. Binding of IL-2 to the IL-2 receptors then induces progression of G1 cells into S 
phase and mitosis (24, 182). The non-permissivity of resting CD4+ T cells has been attributed to 
blocks at different post-entry steps in the viral life cycle, one of the early blocks being the inefficient 
reverse transcription where the viral genomic RNA is copied into cDNA (163, 214). Because the 
original papers (92, 131) describing the antiviral activity of SAMHD1 did not detect SAMHD1 
expression in T cell lines, they assumed that this protein was not effective in T cells. To determine 
whether SAMHD1 imposes a restriction of HIV-1 infection in resting CD4+ T cells, a method for 
SAMHD1 detection by flow cytometry was first established, and was followed up with functional 
experiments focussing on infections with HIV-1 or HIV-2 into which viral Vpx was artificially or 
naturally packaged, respectively.  
The results in this chapter have been published during the course of this thesis and the figures and text 
are modified from (II) and (III). 
 
SAMHD1 Is Expressed in Human CD4+ T cells  
SAMHD1 is expressed in dendritic cells, monocytes and macrophages, but not in T cell lines (e.g 
Jurkat, SupT1 and human peripheral blood acute lymphoid leukemia (HPB-ALL), and it has been 
reported to act as a lineage-specific infection barrier for HIV-1 (92, 131). After establishing a staining 
protocol including a permeabilization procedure suitable for detection of SAMHD1 in primary 
leukocytes by flow cytometry (Fig. 4.13A), we examined expression levels of the protein in PBMC 
and tonsil cells. Using a methanol-based permeabilization protocol, in spite of the proposed lineage 
specificity, we detected endogenous SAMHD1 protein in all nucleated hematopoietic cells among 
PBMCs and in tonsil tissue (Fig. 4.13B). This analysis included resting CD4+ T cells from peripheral 
blood, where we found high levels of SAMHD1 mRNA (not shown) and protein expressed (Fig. 
4.13C). SAMHD1 was also abundantly expressed in explants of human tonsil, a lymphoid tissue 
targeted by HIV-1 in vivo, where the majority of SAMHD1-expressing cells localized to the 
perifollicular region (Fig. 4.13D). 
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Fig. 4.13 Specific detection of SAMHD1 by flow cytometry and immunohistochemistry. (A) Freshly isolated PBMC or 
tonsil cells were fixed, permeabilized using either a saponin- or methanol-based protocol and stained with a rabbit polyclonal 
SAMHD1 antibody or rabbit IgG as a control. A secondary Alexa660-conjugated goat anti-rabbit antibody was used as a 
detection reagent, and cells were analyzed on a FACSCalibur. (B) Freshly isolated PBMC or tonsil cells were fixed, 
permeabilized and stained for SAMHD1 in combination with the respective lineage markers and analyzed by flow cytometry. 
(C) Resting CD4+ T cells were fixed and permeabilized as described in Materials and Methods and stained either with a 
rabbit control serum (left panel) or a rabbit anti-SAMHD1 serum (right panel). After co-staining with a secondary Alexa660-
conjugated goat anti-rabbit antibody and an anti-CD4-FITC mAb, cells were analyzed by flow cytometry. (D) In situ 
expression of SAMHD1 in explants of human tonsil. Left and center, immunohistochemical detection of SAMHD1. Nuclei 
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were counterstained with hematoxylin. GC, germinal center; LW, lymphocyte wall; PR, perifollicular region. Modified from 
reference (II) and (III). 
 
Vpx Degrades Endogenous SAMHD1 in Resting CD4+ T cells 
Several studies have demonstrated that SAMHD1 is targeted by Vpx for CRL4/DCAF1 ubiquitin 
ligase-mediated proteasomal degradation (12, 92, 131). To assess the ability of Vpx to degrade 
endogenous SAMHD1 in resting CD4+ T cells from healthy donors, we co-expressed SIVmac239 
Vpx (WT Vpx) or the DCAF1 interaction-deficient mutant Q76A (Q76A) with GFP. Upon Vpx co-
expression, we detected a potent and Q76-dependent reduction of SAMHD1 levels by intracellular 
flow cytometry. Low levels of co-expressed GFP and WT Vpx were sufficient to maximally degrade 
SAMHD1 and diminished intracellular SAMHD1 levels by more than 90% (Fig. 4.14). 
 
Fig. 4.14 Vpx mediates SAMHD1 depletion in resting CD4+ T cells. Quantification of intracellular SAMHD1 levels in 
nucleofected resting CD4+ T cells. Cells were nucleofected to co-express GFP in combination with WT Vpx, Vpx Q76A or 
an empty control and 16 h later analyzed for SAMHD1 expression in relation to GFP expression by flow cytometry. 
Modified from (II).  
 
SAMHD1 Depletion is Specific for HIV-1 Virions with Incorporated Vpx WT or for HIV-2 WT 
Virions 
To address the question whether Vpx would allow HIV-1 to infect resting human CD4+ T cells, we 
generated a replication-competent HIV-1 GFP reporter virus (HIV-1* GFP), into which we 
incorporated Vpx by adding a Vpx-interaction motif into the Gag p6 domain of the CXCR4-tropic 
HIV-1 strain NL4-3. When resting CD4+ T cells were infected with wild-type Vpx-carrying HIV-1 or 
its mutant variant (Vpx Q76A) incorporated (Fig. 4.15A), massive depletion of the cellular SAMHD1 
pools were observed for wild-type Vpx-incorporated HIV-1 but not for the Vpx Q76A mutant 
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derivative (Fig. 4.15B). The Q76A-dependent SAMHD1 depletion correlated with enhanced 
infectivity (not shown). Similarly, successful HIV-2 infection correlated with Vpx-dependent 
degradation of SAMHD1 (Fig. 4.15C).      
 
 
Fig. 4.15 SAMHD1 depletion is specific for HIV-1 virions with incorporated Vpx WT or for HIV-2 WT virions. (A) 
Immunoblot analysis of HIV-1* GFP virions carrying no Vpx (Control), Vpx WT or Q76A. (B) Resting CD4+ T cells were 
challenged with identical infectious units of the HIV-1 virions in Fig.4.15A and analyzed for intracellular SAMHD1 levels 1 
day post infection. (C) SAMHD1 levels in resting CD4+ T cells were monitored by flow cytometry 3 days post-challenge 
with either HIV-2ROD9 (WT) or the Vpx-defective, isogenic counterpart (ΔVpx). Modified from (II). 
 
Susceptibility of Resting CD4+ T Cells to Vpx-Carrying HIV-1 Is Paralleled by Proteasomal 
Degradation of SAMHD1 
To explore the relationship between Vpx-mediated degradation of SAMHD1 and permissivity to HIV-
1 in resting CD4+ T cells, we followed both parameters over time at a single-cell level. Whereas 
infection with HIV-1* GFP had no effect, SAMHD1 was massively depleted in 20–80% of cells 1 day 
after challenge with HIV-1* GFP plus SIVmac239 Vpx (Fig. 4.16A). This degree of depletion was 
constant until day 3 after infection, when GFP reporter expression indicated proviral integration and 
early viral gene expression (4.3% of cells in Fig. 4.16A). SAMHD1 degradation in resting CD4+ T 
cells was specific to HIV-1* GFP virions containing Vpx; it was observed as early as 6 hours after 
virion challenge and correlated in magnitude with the percentage of GFP+ cells (Fig. 4.16A,B). The 
peptidic virion fusion inhibitor T20 or the CXCR4 antagonist AMD3100 inhibited Vpx-dependent 
HIV-1 HIV-2
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depletion of SAMHD1 (Fig. 4.16C), demonstrating that this process strictly depends on virus entry 
and subsequent release of Vpx. Furthermore, the depletion of SAMHD1 and the enhancement of 
resting T cell infection by virion-packaged Vpx was abrogated by treatment of cells with the 
proteasome inhibitors MG132 (Fig. 4.16C) or ALLN (not shown). 
 
 
Fig. 4.16 Susceptibility of resting CD4+ T cells to Vpx-carrying HIV-1 is paralleled by proteasomal degradation of 
SAMHD1. (A) Time course of SAMHD1 and GFP expression in resting CD4+ T cells after challenge with HIV-1* GFP + 
Vpx (SIVmac239). The percentages of cells in the respective quadrants are shown. (B) Quantification of SAMHD1 
expression in resting CD4+ T cells within the first 22 hours after exposure to HIV-1* GFP with (+ Vpx) or without (Control) 
incorporated Vpx. Data points mark the percentages for cells with low SAMHD1 levels (corresponding to the bottom left 
quadrants in FACS panels shown in A). (C) Effect of proteasome or HIV-1 entry inhibitors on SAMHD1 levels in resting 
CD4+ T cells after exposure to HIV-1* GFP ± Vpx. Resting CD4+ T cells were pretreated for 1 hour with either the 
proteasome inhibitor (PI) MG132 (10 μM), the fusion inhibitor T20 (50 μM) or the CXCR4 antagonist AMD3100 (5 μM) 
before infection with HIV-1* GFP with or without virion-packaged Vpx. Drugs were removed 20 hours later. Shown are the 
percentages of resting CD4+ T cells with low levels of SAMHD1 24 hours after infection for one of three donors. Modified 
from (II). 
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4.3 MOUSE SIGLEC-1 MEDIATES TRANS-INFECTION OF MURINE LEUKEMIA VIRUS IN 
A SIALIC ACID N-ACYL SIDE CHAIN-DEPENDENT MANNER    
The Ig-type lectin Siglec-1 expressed on monocyte-derived DC has been demonstrated to bind to 
glycolipids in the HIV-1 membrane, thereby being able to capture viral particles as well as mediating 
their transfer to permissive CD4+ T cells (100, 168). This process, referred to as trans-infection, 
occurs by a two-step process in which the Siglec-1-expressing cell – which is usually itself non-
permissive to the virus – first captures virus particles and can retain these viruses for a certain period 
of time. Transmission of viral particles is then mediated to permissive neighboring target cells, 
promoting viral dissemination and spread (99). In mice, Siglec-1 is highly expressed on specific 
macrophage subsets in the secondary lymphoid organs (122), and these cells have been described as 
critical for the clearance of viruses from the lymph, and also for initiating humoral immune responses 
(108). In this context, we investigated the role of mouse Siglec-1 in mediating trans-infection of MLV. 
We also studied the interaction between the Siglec-1 receptor and the virus particles, and how this 
interaction depends on the N-acyl side chain of the sialic acids that are exposed in the viral membrane 
gangliosides. 
The following chapter is in preparation for publication and is modified from (IV). 
  
Mouse Siglec-1 is Expressed on Macrophages, Upregulated by IFNα Treatment and 
Mediates MLV Trans-Infection of Lymphocytes  
To explore the expression of Siglec-1 on the cell surface of mouse macrophages, cell line ANA-1 and 
L929-differentiated primary bone marrow-derived macrophages (BMDM) were stained with either rat 
anti-mouse Siglec-1 mAb 3D6.112 or an isotype control mAb and processed for flow cytometry. 
Cells, which had either been left untreated or exposed to mouse IFNα for 48 hours, were analyzed. 
ANA-1 cells exposed low constitutive levels of Siglec-1 on the surface, the expression of which could 
be induced 3- to 5-fold by IFNα stimulation (Fig. 4.17). BMDM expressed markedly higher 
constitutive, but also INFα-responsive levels of the sialic acid-binding Ig-like receptor on their cell 
surface.  
For direct infection or trans-infection studies we employed a replication-competent ecotropic Moloney 
MLV carrying an IRES-egfp element (MLV-GFP) (68). The GFP reporter encoded by this 
recombinant retrovirus is expressed only upon productive infection of target cells. We first 
characterized the susceptibility of the cell lines and primary cells used in this study for direct, 
productive MLV-GFP infection. Virus exposure of the S1A.TB.4.8.2 (S1A.TB) T-cell lymphoma or 
LPS-activated primary mouse splenocytes demonstrated their high-level susceptibility (Fig. 4.18A), 
while neither BMDM (Fig. 4.18A) nor ANA-1 cells (data not shown) were permissive. 
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Fig. 4.17 Siglec-1 is expressed on mouse macrophages in an INFα-responsive manner. ANA-1 cells or L929-
differentiated BMDM were stimulated with 500 U/mL mouse IFNα for 48 hours or left untreated. Mechanically detached 
cells were stained using a PE-conjugated anti-mSiglec-1 mAb or an isotype control mAb and analyzed by flow cytometry. 
Shown are untreated cells (black lines) or IFNα-treated cells (shaded histograms) stained for mSiglec-1 and untreated cells 
(dotted line) stained with the isotype mAb. Modified from (IV). 
 
The inability of MLV to infect non-cycling macrophages is well established (135, 172) and an 
important characteristic to unambiguously assess their role as a virus donor in MLV trans-infection of 
lymphocytes in the current study. To explore the ability of mouse macrophages to capture and trans-
infect MLV-GFP in a Siglec-1-dependent manner, BMDM or ANA-1 cells were first pretreated for 30 
min at 4°C with blocking anti-Siglec-1 or isotype control mAbs, then exposed to MLV-GFP particles 
for 4 hours at 37°C, washed extensively, and subsequently co-cultured with target S1A.TB 
lymphocytes (Fig. 4.18B). Two days later the percentage of GFP-positive S1A.TB cells was analyzed 
by flow cytometry as a quantitative readout for the efficiency of trans-infection. ANA-1 cells and 
BMDM pretreated with the isotype control mAb mediated a robust MLV-GFP trans-infection (Fig. 
4.18C). Their capacity for trans-infection was increased by IFNα pretreatment and this effect 
correlated with their Siglec-1 surface levels (Fig. 4.17 and data not shown). Importantly, MLV trans-
infection was efficiently and specifically blocked when macrophages were pretreated with the anti-
mouse Siglec-1 mAb. Thus, Siglec-1 on the cell surface of BMDM is constitutively expressed, IFNα-
responsive and appears to have the capacity to mediate trans-infection of the simple retroviral 
pathogen MLV to permissive lymphocytes.  
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Fig. 4.18 Siglec-1 supports MLV Trans-Infection. (A) Each of the indicated cell types was infected with MLV-GFP (MOI 
0.1) and two days later analyzed for GFP expression by flow cytometry. (B) Experimental set-up used for the experiments 
depicted in panel D for trans-infection. (C) L929-differentiated BMDM or ANA-1 cells were stimulated with 500 U/mL 
mouse IFNα for 48 hours or left untreated. Cells were pre-incubated with 10 μg/mL of an anti-Siglec-1 mAb or an isotype 
control mAb at 4°C, exposed to MLV-GFP (MOI 0.1) for 4 hours at 37°C and washed three times in PBS. S1A.TB cells were 
then added in a 1:1 ratio to the virus-pulsed macrophage cultures for 48 hours and then analyzed for GFP expression by flow 
cytometry. Data are expressed as the arithmetic means + S.D. (standard deviation) of triplicate samples from one mouse and 
are representative of at least two experiments each performed using 2-3 mice. Modified from (IV).  
 
BMDM From Wild-type, But Not From Siglec-1 Knockout Mice Support MLV Capture and 
Trans-Infection  
To further corroborate the role of mouse Siglec-1 in MLV trans-infection we employed Siglec-1 
knockout (KO) mice, the generation and characterization of which has been reported (155). The 
genotype of mice was determined using an allele-specific PCR (Fig. 4.19A). The absence of Siglec-1 
expression in KO mice carrying the homozygous (-/-) deletion was demonstrated in cultured BMDM 
(Fig. 4.19B) and mCD11b-positive cells of the monocyte/macrophage lineage in a freshly isolated 
lymph node suspension (Fig. 4.19C), in line with previous characterizations (127).  
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Fig. 4.19 Charachterization of Siglec-1 -/- mice. (A) Genotyping of Siglec-1-/- mice (KO mice) by PCR. DNA extracted 
from mouse tails was amplified using an allele-specific PCR. Product sizes of 495 bp or 204 bp are diagnostic for the wild-
type (WT) and knockout (KO) allele, respectively. (B, C) Selected Siglec-1 phenotyping of KO and WT mice: (B) L929-
differentiated BMDM and (C) freshly isolated, mechanically disrupted inguinal lymph nodes were stained for mSiglec-1 
surface expression (in (C) co-stained for mCD11b) and analyzed by flow cytometry. (B) Shown are WT-BMDM (shaded 
histogram) or KO-BMDM (black line) stained for mSiglec-1 and WT-BMDM (dotted line) stained with the isotype mAb. 
From (IV) . 
 
In a comparative assessment of Siglec-1-deficient KO and wild-type (+/+, WT) mice we explored 
whether Siglec-1-dependent capture of MLV particles could be quantified in BMDM. Two 
experimental approaches were taken: BMDM from WT and KO mice were incubated with MLV for 4 
hours at 37°C, washed with PBS, detached by gentle scraping and processed for detection of either 
cell-associated MLV p30
Gag
 structural protein or cell-associated reverse transcriptase (RT) activity. 
For the first approach BMDM were fixed, permeabilized and stained using a rat anti-p30
Gag
 mAb. 
While flow cytometric analysis of MLV-exposed BMDM from KO mice showed only background 
staining (gate R2, Fig. 4.20A and Fig. 4.20B), BMDM from WT-littermates, which had been exposed 
to MLV particles for 4 hours, revealed a robust signal for the p30
Gag
 capsid staining (gate R2, Fig. 
4.20A and Fig. 4.20B). For the second approach BMDM were lysed and processed for a SYBR Green 
I-based product-enhanced RT assay, a method previously developed for the quantitation of 
retroviruses in culture supernatants (162). MLV exposure of WT-BMDM, but not of KO-BMDM, 
resulted in a significant cell-associated RT activity (Fig. 4.20C). Next, BMDM derived from WT and 
KO mice were analyzed side-by-side for their capacity to mediate MLV trans-infection. In line with 
the above antibody-blocking studies (Fig. 4.18C), WT-BMDM efficiently trans-infected S1A.TB T-
lymphocytes and LPS-stimulated splenocytes (Fig. 4.20D). In contrast, KO-BMDM were unable to 
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Fig. 4.20 BMDM from wild-type, but not from Siglec-1 knockout mice support MLV capture and trans-infection. (A-
D) L929-differentiated BMDM from WT and KO mice were exposed to MLV-GFP for 4 hours at 37°C and subsequently 
washed three times with PBS. (A-C) MLV-GFP-pulsed BMDM were detached and analyzed for MLV capture by two 
methods: (A, B) First, pulsed cells (MOI 0.5) were fixed, permeabilized and stained with rat anti-p30Gag mAb followed by an 
Alexa488-conjugated secondary antibody. (A) Flow cytometric dot plots depicting (left panels) the forward- and side 
scattering of light (FSC/SSC) to identify live cells (gate R1) and (right panels) Alexa488 staining to identify cell-associated 
MLV p30Gag (gate R2). The percentage of viable cells within R2 is indicated. (B) Histogram bars depict the arithmetic mean 
+ S.D. of the percentage of p30Gag-positive cells from triplicates. (C) Second, pulsed cells (MOI 0.1) were detached, lysed 
and analyzed for cell-associated RT activity. (D) MLV-GFP-pulsed BMDM were co-cultivated with LPS-activated 
splenocytes at a 1:1 ratio. 48 hours later lymphocytes were analysed for GFP expression by flow cytometry. Data are 
expressed as the arithmetic means + S.D. (standard deviation) of triplicate samples from one KO and one WT mouse and are 
representative of at least two experiments each performed using 2-3 mice. From (IV). 
 
support MLV trans-infection and IFNα stimulation could not overcome this limitation. Together, these 
results demonstrate that primary macrophages from mice are capable of capturing infectious MLV 
particles and of mediating a subsequent trans-infection of lymphocytes in a Siglec-1-dependent 
manner. 
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MLV-GFP Trans-Infection Is an Efficient Process That Preferentially Targets Activated 
Primary B-Cells  
Next, we sought to assess the relative contribution of direct infection and trans-infection to the overall 
infection of cultured primary lymphocytes in the context of a constant multiplicity of infection. 
Furthermore, we tested the impact of two activation protocols for splenocyte cultures, i.e. treatment 
with either LPS and ConA/IL-2, which preferentially stimulate the proliferation of B-cells and T-cells, 
respectively (32, 47) on lymphocytes MLV-GFP susceptibility. WT-splenocyte cultures following 
LPS activation for three days consisted of 64% CD19-positive and 31% CD3-positive cells, expressed 
as fractions within the viable lymphocyte gate. In contrast, stimulation with ConA/IL-2 resulted in 
97% CD3-positive T-cells (Fig. 4.21C).  
Two interesting observations were made: First, in the absence of BMDM only LPS activation allowed 
for a robust direct infection of WT-splenocytes (4 ± 0.80%, Fig. 4.21A), the vast majority of which 
were blasted CD19-positive B cells (99.8%, data not shown). In comparison, the low-level infection of 
the ConA/IL-2-stimulated culture (0.2 ± 0.08%, Fig. 4.21A) represented both T cells (30%) and B 
cells (60%) (data not shown). Second, the experimental set-up in which WT-splenocytes (targets for 
both direct and trans-infection) and BMDM (donor cells for trans-infection), the latter derived from 
either WT or KO mice, were present in the culture at the time of virus addition, revealed that WT-
BMDM were able to markedly boost the overall infection level of lymphocytes (Fig. 4.21A). For LPS-
stimulated splenocytes, the co-culture with WT-BMDM raised the percentage of GFP-positive 
lymphocytes to 14 ± 1.30%, representing a 3- to 5-fold increase over the conditions with splenocytes 
alone or co-culture with Siglec-1-deficient BMDM (Fig. 4.21A). Virtually all infected cells were 
CD19-positive B-cells (Fig. 4.21B).  
Remarkably, co-culture with WT-BMDM resulted also in a notable infection of ConA/IL-2-activated 
splenocytes translating to a 15-fold enhancement over the reference conditions (Fig. 4.21A) with both 
T-cells and B-cells being infected (Fig. 4.21C). Collectively these results indicate that Siglec-1-
dependent trans-infection via macrophages may contribute to a more efficient infection process of 
lymphocytes in the context of a limited number of infectious MLV particles. Moreover, activated 
primary B-cells appear to be a preferential target of direct infection as well as trans-infection of MLV.   
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Fig. 4.21 BMDM-mediated trans-infection of MLV-GFP efficiently targets activated primary B-cells. Splenocytes from 
WT mice were activated with either LPS or ConA/IL-2 for 3 days and then seeded either alone or onto BMDM from WT or 
KO mice in a ratio of 1:1. Cultures were challenged with MLV-GFP (MOI 0.2) and splenocytes analyzed for GFP expression 
48 hours later by flow cytometry. (A) Histogram bars depict the arithmetic means + S.D. (standard deviation) of the 
percentage of GFP-positive, viable cells from triplicates. Experiments were performed using 2-3 KO or WT mice and 
repeated at least twice showing similar results. (B, C) The identity of the MLV-GFP-infected splenocytes was determined by 
co-staining for the lineage markers CD3 (T-cells) and CD19 (B-cells). R1 identifies the viable cells. R2* (red box) identifies 
the MLV-GFP-positive cells and R2 (black box) all viable cells. Dot plots in the lower panels depict the respective 
mCD3/mCD19 stainings. Modified from (IV) . 
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Mouse Siglec-1 and MLV Gag Partially Co-localize in Intracellular Compartments Early After 
Virus Exposure  
Next, we investigated the fate of Siglec-1 and MLV in BMDM early and late after virus exposure by 
co-immunofluorescence microscopy and trans-infection analysis. BMDM derived from WT or KO 
mice were pulsed with either MLV-GFP or MLV-Gag-GFP, for 4 hours at 37°C and then extensively 
washed. The latter virus carries Gag-GFP fusion proteins within the particle. BMDM grown on cover 
slips were either fixed immediately after pulse (“4 hours”) or cultivated for another 20 hours (“24 
hours”) and stained with antibodies to mSiglec-1. At the 4-hour time point, mSiglec-1 and Gag-GFP 
partially co-localized in distinct punctae in WT-BMDM (Fig. 4.22B, upper and middle panels). Two 
phenotypes were frequently observed: A dominant single accumulation of the mSiglec-1 receptor and 
the viral structural protein was observed in 69 % of cells (Fig. 4.22B, upper panels), resembling the 
sac-like compartment reported for human Siglec-1 and HIV p24
Gag
 in myeloid dendritic cells (100). In 
31% of BMDM a more scattered cytoplasmic localization of Siglec-1 and Gag-GFP was noted with up 
to 100 distinct punctae, in which signals for both proteins partially overlapped (Fig.4.22B, middle 
panels). No colocalization of the mSiglec-1/ Gag-GFP-positive punctae with a marker for acidic 
lysosomes was observed (Fig. 4.22E). BMDM from KO mice displayed only background staining for 
mSiglec-1 and at most a few small Gag-GFP signals consistent with their inability to capture and 
trans-infect MLV (Fig. 4.22B, lower panels, Fig. 4.22A). Interestingly, at 24 hours, the frequency and 
intensity of the punctae for both mSiglec-1 and Gag-GFP in WT-BMDM were strongly diminished 
(Fig. 4.22C). 
In parallel to the microscopic analyses we assessed the ability of BMDM to trans-infect S1A.TB cells 
immediately after the virus pulse (“4 hours”) and after the prolonged storage period. Remarkably, 
delayed addition of target T-cells at only 24 hours resulted in a drastic drop in the efficiency of trans-
infection, levels of 2% compared to the condition in which the S1A.TB cells had been added to the 
BMDM at the 4-hour time point (Fig. 4.22A). Neither the loss of capsid signal in immunofluorescence 
nor the drop in trans-infection could be rescued by pre-treating the BMDM with proteasomal or 
lysosomal inhibitors (data not shown). In conclusion, mSiglec-1 and MLV Gag partially co-localize in 
intracellular compartments in BMDM early after virus exposure. Within 24 hours the detection of the 
viral structural protein is greatly diminished coinciding with a marked reduction in the ability of 
pulsed BMDM to trans-infect. 
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Fig. 4.22 Captured MLV particles partially co-localize with Siglec-1 in BMDM early after virus exposure. BMDM 
derived from either WT or KO mice were pulsed with (A) MLV-GFP or (B-E) MLV Gag-GFP, which carries a Gag-GFP 
fusion protein, for 4 hours at 37°C. PBS-washed BMDM were either (A) co-cultivated with S1A.TB-cells added either 
immediately after washing (4 hours) or 20 hours later (24 hours) or (B, C, E) fixed, permeabilised and stained using an 
Alexa647-conjugated anti-Siglec-1 mAb. Representative images for (B, upper panels, 4h) a dominant single accumlated 
MLV Gag/Siglec-1 signal or (B, middle panels, 4h) multiple scattered punctae from WT-BMDM are shown.  (B, bottom 
panel) Images of MLV-Gag-GFP-pulsed KO-BMDM stained for mSiglec-1. (D) The MLV Gag pattern (”scattered” or 
”accumulated”) and frequency of WT-BMDM displaying this phenotype  were quantified. At least 70 cells from each of three 
mice were analysed. (E) The lysosomal marker Lysotracker Red was added to BMDM 30 minutes before fixation. Modified 
from (IV).   
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Biosynthetic Modulation of the N-Acyl Side Chain of Sialic Acid in Virus Producer Cells 
Affects the Ability of MLV Particles for Siglec-1-Dependent Capture and Trans-Infection  
We then sought to functionally explore the role of the sialic acid for the Siglec-1-dependent trans-
infection of MLV at a submolecular level in living cells by employing metabolic oligosaccharide 
engineering  (117, 138). This experimental approach is based on the established ability of synthetic N-
substituted D-mannosamine (ManN) derivatives to act as metabolic precursors for sialic acids with 
structurally altered N-acyl side chains incorporated into cellular glycoconjugates, including sialylated 
gangliosides that are incorporated into budding retroviruses (19, 27). We first pretreated 293T cells 
with six different synthetic N-acyl-modified ManN analogs (Fig. 4.23) or the most common 
physiological precursor, N-Acetyl ManN (ManNAc), for five days at non-toxic concentrations.  
 
Fig. 4.23 N-acyl side chain modifications in ManN derivatives added to virus producer cells. (A) Schematic 
representation of ManNAc and the applied N-substituted ManNs with R indicating the modified N-acyl group. From (IV). 
 
Subsequently, re-seeded cells were transfected with MLV-GFP proviral DNA and cultivated in the 
presence of the respective ManN derivatives for two more days. Released MLV-GFP particles were 
concentrated and purified by ultracentrifugation through a 20% sucrose cushion and cell pellets frozen 
for biochemical characterization. The preparations of MLV-GFP particles released from ManN 
analog-pretreated 293T cells were first titered on S1A.TB T-cells, the binding and infection process of 
which is believed to be mediated by the mCAT receptor in a sialic acid-independent manner (174). 
Next, employing the standard experimental set-up, the MLV-GFP particle preparations were assessed 
for their functionality to be captured by Siglec-1-positive WT-BMDM and to trans-infect S1A.TB T-
cells. In parallel, the inocula of the different MLV-GFP stocks were used to infect S1A.TB T-cells 
directly (Fig. 4.24A), confirming that comparable infectious titers had indeed been applied. Striking 
functional differences were however observed for capture and trans-infection: MLV-GFP particles 
released from 293T cells pretreated with N-butanoyl, N-isobutanoyl, N-glycolyl, or N-pentanoyl- 
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Fig. 4.24 Diminished capture and transfer of MLV particles derived from producer cells carrying certain N-acyl-
substituted sialic acids. (A) S1A.TB cells were directly infected with MLV-GFP stocks (MOI 0.1) produced in the absence 
or presence of the indicated ManN analogs and analyzed two days later for GFP expression.  (B-D) WT-BMDM were pulsed 
with  MLV-GFP stocks (B: MOI 0.5; C, D: MOI 0.1) produced in the absence or presence of the indicated ManN analogs for 
4 hours at 37°C. Washed cells were then either analyzed for MLV capture by (B) quantification of p30Gag-positive cells by 
flow cytometry or (C) cell-associated RT activity, in principle as reported in the legend to Fig. 4.20, or (D) used for trans-
infection of S1A.TB cells. Data are expressed as the arithmetic means + S.D. (standard deviation) of triplicate samples from 
one mouse and are representative of at least two experiments each performed using 2-3 mice. (E) Correlation between the 
relative efficiency of virus capture (data depicted in panels B, C) and trans-infection (panel D) for the 10 different MLV-GFP 
stocks. Pearson correlation coefficients and significance values were calculated by applying the two-tailed, unpaired 
Student’s t-test. Modified from (IV). 
 
modified sialic acid precursor analogs were only inefficiently captured by BMDM, while N-propanoyl 
or N-cyclopropylcarbamyl ManN treatments had no or only slight effects (Fig. 4.24B-D). Levels of 
cell-associated MLV p30
Gag
 staining and cell-associated RT activity were reduced by up to 92% (Fig. 
4.24B, C) and these capture readouts strongly correlated (Fig. 4.24E, r=0.91, p=0.0008). In support of 
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a cardinal role of virus capture for the efficiency of subsequent trans-infection, levels of MLV-GFP 
infection in S1A.TB cells were markedly reduced for viruses derived from producer cells exposed to 
the N-butanoyl, N-isobutanoyl, N-glycolyl, or N-pentanoyl ManNs (Fig. 4.24D) and these infection 
levels correlated with both readouts for virus capture (Fig. 4.24E-G). Collectively, these results 
suggest that biosynthetic engineering of glycoconjugates in virus-producer cells is a feasible strategy 
to alter the composition of sialylated glycolipids and glycoproteins within the envelope of viruses that 
bud from the plasma membrane allowing their functional characterization. Specifically, this approach 
allowed us to identify the N-acyl side chain of sialic acid as a critical determinant for the mSiglec-1-
MLV particle interaction. 
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5. DISCUSSION 
5.1 WIDESPREAD CD317-EXPRESSION IN HUMAN TISSUES – BUT NOT IN HIV-1 
TARGET CELLS  
This chapter has been published during the course of this thesis and is modified from (I).  
Our in vivo expression profiling of the antiviral restriction factor and potential tumor-targeting antigen 
CD317 in nontransformed human organs documented widespread tissue expression on a number of 
specialized cell types. This stands in contrast to a previous report suggesting selective expression of 
CD317 on the surface of nontransformed, terminally differentiated B cells (71). Explicitly, that earlier 
study described a lack of CD317 expression on PBMCs, lymph nodes, liver, spleen, kidney, and heart, 
applying the identical anti-HM1.24 mAb. Although we can confirm CD317 expression on plasma 
cells, our study identified many additional CD317+ cell types and tissues throughout the body, greatly 
expanding the expression profile of this protein. We suspect that differences in the sensitivity of 
immunodetection might underlie this discrepancy. Our findings refute the widely held belief that the 
constitutive expression of CD317 in humans is highly restricted, a misperception that has spurred 
antibody-based immunotherapy strategies for multiple myeloma and certain solid human tumors (28, 
71, 103, 114, 158), (8, 22, 113, 181, 201). In line with our findings, a previous Northern blot analysis 
documented CD317 mRNA in several tissues, including pancreas, liver, lung, and heart (96).  
 
5.1.1 CD317 is expressed on cell types targeted in vivo by enveloped viruses 
The role of CD317 in the control of virus replication in vivo is not completely understood; however, 
several lines of evidence point to an important antiviral capacity of CD317 in mammals. First, various 
completely unrelated viruses (i.e., lentiviruses, herpes viruses, filoviruses, orthomyxoviruses) encode 
CD317 antagonists with distinct modes of action to overcome the restriction imposed by CD317 (48). 
Second, anti-CD317 activities have evolved in three different lentiviral genes (nef, env, and vpu) 
(120), implying a critical role of CD317 in the lentivirus–host adaption and cross-species transmission. 
In support of this notion, a nef-deleted simian immunodeficiency virus rapidly acquired compensatory 
changes in gp41 in infected rhesus macaques that restored resistance to CD317/tetherin (178). Third, 
CD317 proteins from different species show evidence of positive selection, consistent with adaptations 
in response to invading viruses (120). The present study establishes that CD317 is expressed on a 
variety of specialized cell types known to be in vivo targets for enveloped viruses. For example, 
vascular endothelial cells, identified as high CD317 expressers, are major replication sites of 
hemorrhagic fever viruses (e.g., Lassa virus, Ebola virus, Hantaan virus), as well as KSHV, vesicular 
stomatitis virus, and herpes simplex virus (197). In the lung, CD317+ type I and II alveolar 
pneumocytes are targeted by various respiratory pathogens, including influenza viruses (79), severe 
acute respiratory syndrome coronavirus (81), and respiratory syncytial virus (107). Remarkably, cell 
culture experiments have already demonstrated that CD317 can exert antiviral activity against some of 
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these pathogens, including Lassa virus, vesicular stomatitis virus, influenza A virus, Ebola virus, and 
KSHV (48, 210). Intriguingly, the latter three viruses encode CD317 antagonists, indicating 
evolutionary adaptation of these pathogens. In addition, hepatocytes, monocytes, epithelial cells, 
terminally differentiated B cells, and bone marrow stromal cells, which express CD317 in vivo, are 
sites of replication for diverse viruses. The insights provided by the current expression profiling 
underscore CD317’s in vivo relevance as an antiviral factor and suggest the possibility of future 
studies to investigate whether some of these other viruses are affected by this restriction factor and/or 
have evolved antagonists.  
 
5.1.2 Origin of Vpu’s function to antagonize CD317 
Although HIV encodes potent CD317 antagonists, namely Vpu and Env, it remains unclear where the 
virus actually encounters CD317 in vivo. In secondary lymphoid organs and gut epithelium, major cell 
types for productive infection (i.e., CD4 T cells, macrophages, dendritic cells, and pDC) did not 
express significant levels of CD317. Although the subset of CD16+ monocytes might serve as an HIV-
1 reservoir (31), it seems unlikely that this minor population of infected, CD317+ cells exerts 
sufficient selection pressure for HIV to preserve CD317 antagonistic activities. It is conceivable that 
systemic responses in HIV-infected individuals enhance CD317 expression in CD4 T cells, or that 
susceptible cells in other anatomic compartments, such as genital mucosa, show a different profile of 
constitutive expression and regulation. In support of the former notion, a previous study found that 
CD4 T cells in blood and lymph nodes from African green monkeys and rhesus macaques rapidly up-
regulated CD317 mRNA after simian immunodeficiency virus infection (101). 
  
5.1.3 In vivo regulation of CD317 expression 
Secretion of type I IFNs from virus-infected cells is a hallmark of antiviral immunity. Potential target 
cells of infection that receive these signals increase expression of IFN-stimulated genes, many of 
which are linked to antiviral functions (69, 105, 191). The IFN responsiveness of CD317 in cultured 
primary cells is subtle; monocyte-derived macrophages up-regulated CD317 mRNA levels by less 
than twofold (78), and protein levels were elevated only slightly (145). Moreover, in the present study, 
type I IFN stimulation increased CD317 levels on isolated pDC only moderately, and CD317 
expression on lymphocytes in tonsil was largely unresponsive to IFN. In line with the latter 
observation, virtually no co-expression of CD317 and the strictly IFN-induced restriction factor MxA 
was observed in tonsillar and pulmonary tissue. In contrast, the abundant MxA–CD317 co-expression 
in vascular endothelial cells is consistent with an IFN-mediated co-stimulation. Taken together, these 
findings suggest that type I IFNs may be a key regulator of CD317 expression only in certain cell 
types and tissues. Conceivably, other cytokines (e.g., TNF-α, IL-1, IL-6) secreted by the host in 
response to a viral insult may possibly trigger CD317 expression in vivo (156).  
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Along with antiviral activity, other functions of CD317 are starting to emerge for which knowledge of 
CD317’s in vivo expression profile is of interest, including its proposed capacity as a negative trans 
regulator of pDC responses (25) and as an organizer of the subapical actin cytoskeleton in polarized 
epithelial cells (173). In support of the relevance of the latter function, gallbladder epithelial cells, 
which express high levels of CD317 in situ (Figs. 4.4A and 4.5), are characterized by a particularly 
pronounced structural polarization (157). From a therapeutic perspective, the widespread expression of 
human CD317, in particular its presence on a number of vital cell types, calls into question the 
proposed development of tumor-selective, CD317-based targeting strategies. 
 
5.2 SAMHD1 EXERTS ANTIVIRAL ACTIVITY IN RESTING CD4+ T CELLS  
SAMHD1 has been reported to potently restrict productive HIV-1 infection at an early stage of the viral 
replication cycle in monocytes and DC (92, 131), but was assumed not to be effective in T cells due to 
its absence in several transformed T cell lines. Previous immunofluorescence analyses of SAMHD1-
expressing cells demonstrated a clear nuclear localization of the protein (17). We could show that 
SAMHD1 is abundantly expressed in resting CD4+ T cells circulating in peripheral blood and residing 
in lymphoid organs, and the protein could be found both in the nuclear and in the cytoplasmic 
compartment (II).  
 
5.2.1 Monitoring restriction factor activity and regulation by flow cytometry 
To monitor SAMHD1 levels during the course of an infection with a GFP-encoding virus, and to 
investigate its in vivo expression levels in specific cell types, it was important to establish a staining 
protocol for flow cytometry for this mainly nuclear protein. Depending on the protein’s location inside 
the cell, different staining strategies work differently well. Saponin-based permeabilization methods are 
commonly used to detect intracellular antigens such as cytokines, but nuclear antigens usually require 
stronger permeabilization conditions that allow the antibody to enter the nucleus and access the 
epitope(s). For this purpose, we employed a methanol-based permeabilization protocol normally used 
for phosphoepitope detection by flow cytometry (126). This permeabilization strategy was required to 
enable detection of a distinct SAMHD1+ population, whereas a saponin-based method yielded only dim 
staining. Recent findings demonstrate SAMHD1 antiviral activity to be determined by its 
phosphorylation status, where phosphorylation at residue T592 renders SAMHD1 incapable of blocking 
retroviral infection (34, 204). This phosphorylation was suggested to be induced upon T cell activation, 
whereas treatment with type-I IFN resulted in reduced phosphorylation (34). Detection of phospho-
SAMHD1 by flow cytometry could be a useful tool for monitoring – at a single cell level – 
phosphorylation status and antiretroviral activity of SAMHD1 in primary cells, although this would 
require further optimization and establishment of activation and/or inhibition protocols.  
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5.2.2 SAMHD1 restricts HIV-1 infection in resting CD4+ T cells and is depleted by Vpx  
The data showing that Vpx, delivered to primary resting CD4+ T cells either by transfection or by 
infection using HIV-1 or HIV-2 virions into which viral Vpx was artificially or naturally packaged, 
respectively, was able to deplete endogenous SAMHD1 and in the latter case overcome the restriction, 
suggest that HIV-1 reverse transcription is actively suppressed in resting human CD4+ T cells, and that 
SAMHD1 is a cellular factor that is responsible for this restriction. When primary resting CD4+ cells 
were infected with a Vpx-carrying HIV-1* GFP virus and followed over a 3 days’ time course, GFP+ 
cells were detected exclusively within the population of cells containing low amounts of SAMHD1, 
whereas the residual cell population expressing high amounts of SAMHD1 remained refractory to HIV-
1 infection. Virion-incorporated Vpx seemed insufficient to render all resting CD4+ T cells permissive 
for HIV-1 infection, suggesting either additional blocks insensitive to Vpx-mediated counteraction (60, 
74, 111, 185, 209), or SAMHD1 depletion by defective virions still carrying Vpx.  
 
5.2.3 SAMHD1’s antiviral action    
SAMHD1 was first characterized as a deoxyribonucleotide triphosphate (dNTP) triphosphohydrolase, 
an activity that localized to the HD-domain of the protein (70, 166). Accordingly, alleviating the 
SAMHD1 block of HIV-1 infection by depletion of SAMHD1 correlated with a loss of dNTPase 
activity and increased dNTP pools in myeloid cells (132). More recently, a second enzymatic function 
of SAMHD1 has been identified; apart from cleaving monomeric dNTPs, the HD-domain also exhibits 
exonuclease activity against single-stranded DNA and RNA and can thus degrade poly(ribo)nucleotides 
(10). Interestingly, recent studies claim that phosphorylation of T592 in SAMHD1, relieving the anti-
HIV restriction, has no impact on dNTPase activity (204). This argues against a mechanistic role of 
dNTP depletion in HIV-1 restriction which is consistent with the relatively moderate changes of dNTP 
levels observed in our work (II). It would be interesting to investigate whether phosphorylation of this 
residue affects (decreases) the exonuclease activity, because that would open up for the possibility that 
SAMHD1 restricts HIV-1 replication by degrading the viral genetic components. Interestingly, an even 
more recent study suggests that the RNase function of SAMHD1 may be primarily responsible for its 
restriction activity. This study also demonstrated that phosphorylation of SAMHD1 at T592 decreases 
the RNase activity of the protein, this correlating with impaired HIV-1 restriction (175). More research 
is necessary to identify and characterize the possible HIV-1 polynucleotide intermediates (RNA, DNA 
or RNA-DNA hybrids) that are recognized and cleaved by SAMHD1. Resting CD4+ T cells constitute a 
large pool of noncycling cells in secondary lymphoid organs. In HIV-1 infection, these cells are 
“bystanders” that only become abortively infected – something that SAMHD1 might be partly 
responsible for. After infection is aborted in these cells they undergo cell death, causing massive T cell 
depletion, destruction of the lymphoid tissue, and eventually AIDS (53). Recent studies (44, 45, 146) 
describe how HIV-1 DNA products generated during this abortive infection can be sensed by the 
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cytoplasmic DNA sensor IFI16 (see section 1.1.2.2), this triggering CD4+ T cell death through an 
inflammatory cell death pathway called pyroptosis. More research is also needed to investigate whether 
additional sensors of nucleic acids are involved in mediating T cell immunopathology and AIDS 
pathogenesis.        
 
5.3 SIGLEC-1+ MACROPHAGES MEDIATE MLV TRANS-INFECTION  
This chapter is in preparation for publication and is modified from (IV).  
In the current study we demonstrate that Siglec-1 is a key receptor on primary mouse macrophages for 
capture of the enveloped retrovirus and mouse pathogen MLV and its efficient trans-infection of 
interacting lymphocytes. Terminal sialic acid residues on plasma membrane-derived sialyllactose-
containing gangliosides that are incorporated into the envelope of budding retroviral particles are the 
key interaction moiety with the lectin receptor Siglec-1. Using metabolic engineering we introduced 
various N-acyl modified sialic acids into glycoconjugates of virus producer cells and demonstrate that 
for some substitutions newly produced MLV particles were functionally impaired for Siglec-1-
dependent capture and trans-infection. This highlights the use of sialic acid precursor analogs as a 
feasible approach to study in a native environment the impact of submolecular modifications in 
glycoconjugates incorporated into enveloped viruses and identifies the N-acyl side chain as a critical 
determinant for the mSiglec-1-MLV interaction. Collectively, mSiglec-1 is an important receptor for 
the sialic acid-dependent macrophage/lymphocyte trans-infection of MLV ex vivo.  
 
5.3.1 Virus capture: enforcing or restricting viral spread? 
Macrophages and dendritic cells patrol peripheral mucosal sites recognizing, capturing and processing 
potential pathogens into antigenic peptides for MHC class II presentation to CD4 T-cells in lymphoid 
tissue (5). Landmark studies by Geijtenbeek and colleagues proposed that HIV-1 usurps this natural 
DC function in the newly infected host by “hiding” inside DC, which traffic to lymphoid organs, 
probably taking advantage of the formation of DC-/T-cell conjugates to promote its replication and 
spread (64, 65, 130). Today it is widely believed that human DC capture and internalize infectious 
HIV particles into clustered “storage” compartments and subsequently transfer these virions to 
neighboring T-cells at virological synapses (63, 99). In contrast to the virus-promoting scenario 
proposed for HIV, Siglec-1-positive sinus macrophages residing underneath the lymph node capsule 
were shown to act as gatekeepers at the lymph-tissue interface capturing and trans-presenting lymph-
borne viruses, including vesicular stomatitis virus (VSV), to migrating B-cells in the underlying 
follicles leading to activation of effective antiviral humoral immune responses (108). Furthermore, 
these macrophages also appear to prevent VSV spread and fatal neuroinvasion by additional innate 
mechanisms (93). Of note, Siglec-1 in these studies was used as a marker for this subset of 
macrophages and not explored as a bona fide virus-binding receptor. 
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5.3.2 Siglec-1 transfers MLV efficiently via a short-term storage compartment 
In contrast to the notion of an intracellular storage compartment for captured viruses that may be 
capable of efficient trans-infection of HIV-1 for up to 4 days (64, 130), Cavrois and colleagues 
provided evidence that virions bound to the surface of monocyte-derived DC or CD34-derived 
Langerhans cells, and not internalized HIV-1, was the major source of infectious virions transmitted in 
trans (26). While these authors also detected large amounts of internalized HIV-1 particles by confocal 
microscopy, they suggest that this may be a dead end for trans-infection. These authors also reported a 
marked drop of HIV-1 trans-infection efficiency of MDDC within a few hours, resembling our 
observations with MLV. From another perspective, given the unique subanatomical localization of 
Siglec-1-positive mouse macrophages in the subcapsular sinus a long-term storage of captured 
infectious virus may not be critical for interaction and virus transmission to closely adjacent B-
lymphocytes in the lymph follicles, which appear to be the preferential target cell of MLV, at least in 
vitro. A central question for the process of trans-infection is the relative efficiency of this process 
compared to direct infection. For HIV-1 MDDC-trans-infection has been suggested to be particularly 
effective for minimal virus doses that alone may not be sufficient for productive infection of CD4 T-
cells by direct infection (64). Our results for MLV support this notion: The Siglec-1-dependent trans-
infection of activated primary lymphocytes via BMDM, compared to direct infection, was 4- to 15-
fold more efficient. Together, it will be fascinating to compare WT and Siglec-1 KO mice for the 
ability to support MLV replication and pathogenesis via lymphatic and intravenous challenge routes.  
 
5.3.3 Pretreatment of MLV producer cells with synthetic sialic acid precursors modified in the 
N-Acyl side chain alters Siglec-1 mediated capture and trans-infection  
To our knowledge the current study for the first time investigated the functional impact of 
metabolically modified sialic acids in virus producer cells on newly produced viruses, supposedly 
carrying cell-derived glycoconjugates. To determine up to which degree the synthetic sialic acids had 
been incorporated into the 293T producer cell membrane, a quantification of the N-substituted sialic 
acids in glycolipids and glycoproteins by LC-MS/MS is currently being undertaken. Unfortunately, 
these analyses could not be sufficiently up-scaled to quantify the abundance of modified sialic acids 
also in highly purified MLV particles. Analysis of the lipid content of HIV-1 and MLV particles 
indicated that the overall lipid content of these retroviruses mostly matched that of the plasma 
membrane, with some lipids being enriched including cholesterol, ceramide, and GM3 (19, 27). 
Notably, a single HIV-1 virion was estimated to contain ~12,000 sialylactose-containing GM3 
molecules which may constitute the primary interactor with the lectin receptor (99). The only 
micromolar affinity of Siglec-1 for different sialylated ligands was postulate to result in high-avidity 
binding by receptor and ligand clustering (38). This may also be true for the interaction with viruses: 
HIV-1, bound initially over the entire plasma membrane, subsequently accumulated in many instances 
at one pole of the cell (97). Several lines of evidence suggest that the metabolically engineered 
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gangliosides carrying N-acyl modified sialic acids were indeed incorporated into MLV particles: First, 
the sialic acid-independent mCAT-mediated direct infection of lymphocytes was comparable for all 
MLV preparations, while particles derived from N-butanoyl, N-isobutanoyl, N-glycolyl, or N-
pentanoyl ManN-treated cells displayed grossly reduced capacities for the sialic acid-dependent 
mSiglec-1-mediated capture and trans-infection. Second, in agreement with these functional analyses, 
both in vitro-interaction studies of sialylated ligands with Siglec-1 (115, 116, 122) and molecular 
modeling studies of mSiglec-1 in complex with sialic acid derivatives (Fig. 5.3) indicated reduced 
binding affinity for the N-glycoyl but not for N-propanoyl substitution. Three-dimensional models of 
mSiglec-1 in complex with Neu5Ac, Neu5Gc, Neu5Prop and Neu5But were generated and, notably, 
all ligands could be accommodated in the binding site without steric clashes (Fig. 5.3A). Based on 
these structures two different computational methods were applied to model an influence of the N-acyl 
side chain modifications on the binding affinity. In a molecular dynamics (MD)-based approach the 
relative binding strength of the ligands was estimated by calculation of the average potential 
interaction energy (Fig. 5.3B).  
As an alternative method to predict the relative binding affinities a ‘docking and post-scoring’ 
approach was applied. Post-scoring of the docked poses was performed using the modeling software 
SeeSAR. The values of the estimated affinity (Fig. 5.3B) showed a similar trend as found in the MD-
based approach. Neu5Gc and Neu5But were predicted to have the lowest affinity for mSiglec-1 by 
both methods. According to this prediction Neu5Ac and Neu5Prop have most likely similar binding 
affinity. Thus, in agreement with the functional analyses, these crystal structure-based molecular 
modeling studies suggest reduced binding affinities for N-butanoyl and N-glycoyl, but not for N-
propanoyl sialic acid side chain modifications for the interaction with mSiglec-1.  
MLV particles that were captured and trans-infected lymphocytes to a significantly lower extent than 
control particles were all released from cells pretreated with ManN derivatives in which the N-acyl 
side-chain was elongated with more than one carbon, this suggesting that bulkiness of this side-chain 
might affect the affinity for Siglec-1. However, pretreatment with N-cyclopropylcarbamyl ManN – 
that contains a cyclopropyl group – notably, did not result in reduced capture or trans-infection. A 
potential reason for this is that treatment with this precursor analog might not have resulted in 
sufficient incorporation of the modified sialic acid in the virus producer cell membrane. The current 
LC-MS/MS analysis will hopefully provide answers to this question. Further, molecular modeling and  
in vitro-interaction studies of sialylated ligands with Siglec-1 could also be employed to investigate 
the Neu5Cyclopropylcarbamyl-Siglec-1 interaction.   
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Fig. 5.3 Molecular modeling of structural interaction, interaction potentials and binding affinities of mSiglec-1 in complex 
with sialic acid derivatives. (A) Three-dimensional models of mSiglec-1 in complex with Neu5Ac, Neu5Gc, Neu5Prop and 
Neu5But were generated. (B) Relative potential interaction energies and SeeSAR affinity scores. Data generated by Martin 
Frank, Biognos, Gothenburg, Sweden. From (IV). 
Neu5Gc naturally occurs in mice, but not in humans (18). Interestingly, while both resting T-cells and 
B-cells preferentially carry Neu5Gc in α-2,6-linkage, activation results in marked changes in 
glycosylation including a shift to Neu5Ac in α-2,3-linkage (150, 151). As a result, expression of 
Siglec-1 and Siglec-F ligands is enhanced on these lymphocytes. These changes may of course also be 
highly relevant for MLV: On one hand, the surface expression of selective ligands fosters the 
interaction of activated lymphocytes with Siglec-1-positive macrophages, increasing the likelihood for 
trans-infection. On the other hand, MLV replicates in these Neu5Ac-containing proliferating B- and T 
cells, leading to the release of Siglec-1-interaction-competent virions.  
Collectively, results from the current study and the availability of Siglec-1-knockout mice provide the 
basis to explore the role of Siglec-1 and the process of trans-infection in general for spread and 
pathogenesis of MLV in vivo. 
 
A
B
Relative Potential Interaction Energies and SeeSAR Affinity Scores
Ligand Relative Potential
Interaction Energy [kcal/mol]
SeeSAR
Affinity Score [mM]
Neu5Ac 0 5
Neu5Prop 5.5 12
Neu5But -6.2 26
Neu5Gc -5.8 33
The relative average potential interaction energies were calculated from 50 ns MD
simulations in water (higher values means better binding) and the average estimated affinity
values calculated by SeeSAR (lower values means better binding).
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6 CONCLUDING REMARKS 
Viruses are intracellular parasites, and the viral genome must therefore enter a cell in order to 
sucessfully replicate. This process starts with adherence of the virus particles to the plasma membrane 
of the cell and this occurs through binding to receptor molecules on the cell surface. After the virus 
enters the cell, its infectious cycle continues with replication of the genome followed by assembly of 
new infectious particles. Throughout this process, host factors can alter the efficiency of the different 
steps required for productive infection. By use of different experimental approaches, the work 
presented in this thesis has focused on characterizing the expression and function of three host proteins 
which have shown potential to modulate retroviral infection; CD317, SAMHD1 and Siglec-1.  
Using a tissue microarray-based method for in situ-detection of CD317 protein, this work identified 
several previously unknown possible interaction sites of enveloped viruses with this antiviral 
restriction factor (I). An important previously unknown interaction site between virus and host factor 
was also found for the early restriction factor SAMHD1. Its abundant expression in resting CD4+ T 
cells prompted further investigations of SAMHD1’s antiviral activity in these cells and we could 
demonstrate that HIV-1 replication is restricted, at least partly, by SAMHD1 in this cell type (II). Our 
study on the sialic acid-binding surface receptor Siglec-1 confirmed that this protein is an important 
mediator of retroviral trans-infection. MLV released from cells treated with synthetic sialic acid 
precursor analogs showed different capacities for Siglec-1 mediated capture and trans-infection, and 
the N-acyl side chain of sialic acid was demonstated to be important for the mouse Siglec-1-MLV 
interaction (IV).       
The findings described here give rise to several important questions. The widespread tissue-expression 
of CD317, and – at the same time – lack of its expression on CD4+ HIV-1 target cells, first of all 
motivate further studies to re-evaluate CD317’s suitability as a selective target for immunotherapy in 
B-cell cancers, but also raise questions about Vpu and its presupposed evolutionary arms race with 
CD317. Thus far it remains unclear where the virus actually encounters CD317, yet HIV-1 encodes 
this CD317 antagonist, suggesting that evolutionary pressure has been exerted by the restriction factor 
in vivo. To investigate where such an encounter might have occurred, a more detailed analysis of HIV-
target cells in other tissues than the already examined, including the genital mucosa, should be 
performed. The mechanistic details on how SAMHD1 imposes retroviral restriction are still not fully 
understood. However, our results demonstrating that SAMHD1 restricts HIV-1 replication in resting 
CD4+ T cells contribute to the active field of research focused on elucidating the mechanisms for 
detection and restriction of incoming viral genomes. Our findings that mouse Siglec-1 is an important 
receptor for mediating trans-infection of MLV, strengthens the notion that this receptor, has the 
capability to influence viral spread. Further studies using Siglec-1-/- mice will likely investigate 
whether these results transfer to also having an impact on tissue dissemination and pathogenesis in 
vivo.  
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Collectively, the work presented in this thesis characterizes the expression and function of three host 
factors that can act as modulators of retroviral infection. The findings described here thereby 
contribute to the overall understanding of how virus attachment receptors and anti-viral restriction 
factors influence the chances for viruses to successfully replicate.   
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